PMC:7317273 / 8662-15144 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T53","span":{"begin":330,"end":334},"obj":"Body_part"},{"id":"T54","span":{"begin":336,"end":357},"obj":"Body_part"},{"id":"T55","span":{"begin":353,"end":357},"obj":"Body_part"},{"id":"T56","span":{"begin":431,"end":435},"obj":"Body_part"},{"id":"T57","span":{"begin":550,"end":565},"obj":"Body_part"},{"id":"T58","span":{"begin":567,"end":589},"obj":"Body_part"},{"id":"T59","span":{"begin":584,"end":589},"obj":"Body_part"},{"id":"T60","span":{"begin":708,"end":730},"obj":"Body_part"},{"id":"T61","span":{"begin":725,"end":730},"obj":"Body_part"},{"id":"T62","span":{"begin":925,"end":936},"obj":"Body_part"},{"id":"T63","span":{"begin":937,"end":959},"obj":"Body_part"},{"id":"T64","span":{"begin":954,"end":959},"obj":"Body_part"},{"id":"T65","span":{"begin":1063,"end":1084},"obj":"Body_part"},{"id":"T66","span":{"begin":1080,"end":1084},"obj":"Body_part"},{"id":"T67","span":{"begin":1267,"end":1281},"obj":"Body_part"},{"id":"T68","span":{"begin":1282,"end":1304},"obj":"Body_part"},{"id":"T69","span":{"begin":1299,"end":1304},"obj":"Body_part"},{"id":"T70","span":{"begin":1380,"end":1382},"obj":"Body_part"},{"id":"T71","span":{"begin":1503,"end":1525},"obj":"Body_part"},{"id":"T72","span":{"begin":1520,"end":1525},"obj":"Body_part"},{"id":"T73","span":{"begin":1757,"end":1768},"obj":"Body_part"},{"id":"T74","span":{"begin":1786,"end":1791},"obj":"Body_part"},{"id":"T75","span":{"begin":1967,"end":1977},"obj":"Body_part"},{"id":"T76","span":{"begin":1972,"end":1977},"obj":"Body_part"},{"id":"T77","span":{"begin":2039,"end":2041},"obj":"Body_part"},{"id":"T78","span":{"begin":2124,"end":2135},"obj":"Body_part"},{"id":"T79","span":{"begin":2161,"end":2165},"obj":"Body_part"},{"id":"T80","span":{"begin":2369,"end":2374},"obj":"Body_part"},{"id":"T81","span":{"begin":2647,"end":2651},"obj":"Body_part"},{"id":"T82","span":{"begin":2900,"end":2904},"obj":"Body_part"},{"id":"T83","span":{"begin":2973,"end":2975},"obj":"Body_part"},{"id":"T84","span":{"begin":3172,"end":3177},"obj":"Body_part"},{"id":"T85","span":{"begin":3442,"end":3452},"obj":"Body_part"},{"id":"T86","span":{"begin":3447,"end":3452},"obj":"Body_part"},{"id":"T87","span":{"begin":3677,"end":3682},"obj":"Body_part"},{"id":"T88","span":{"begin":3695,"end":3709},"obj":"Body_part"},{"id":"T89","span":{"begin":3703,"end":3709},"obj":"Body_part"},{"id":"T90","span":{"begin":3884,"end":3888},"obj":"Body_part"},{"id":"T91","span":{"begin":4123,"end":4128},"obj":"Body_part"},{"id":"T92","span":{"begin":4756,"end":4773},"obj":"Body_part"},{"id":"T93","span":{"begin":4768,"end":4773},"obj":"Body_part"},{"id":"T94","span":{"begin":4779,"end":4793},"obj":"Body_part"},{"id":"T95","span":{"begin":4794,"end":4800},"obj":"Body_part"},{"id":"T96","span":{"begin":4844,"end":4846},"obj":"Body_part"},{"id":"T97","span":{"begin":5070,"end":5074},"obj":"Body_part"},{"id":"T98","span":{"begin":5311,"end":5316},"obj":"Body_part"},{"id":"T99","span":{"begin":5414,"end":5416},"obj":"Body_part"},{"id":"T100","span":{"begin":5507,"end":5509},"obj":"Body_part"},{"id":"T101","span":{"begin":5559,"end":5561},"obj":"Body_part"},{"id":"T102","span":{"begin":5673,"end":5678},"obj":"Body_part"},{"id":"T103","span":{"begin":5731,"end":5733},"obj":"Body_part"},{"id":"T104","span":{"begin":6097,"end":6102},"obj":"Body_part"},{"id":"T105","span":{"begin":6277,"end":6291},"obj":"Body_part"},{"id":"T106","span":{"begin":6293,"end":6295},"obj":"Body_part"},{"id":"T107","span":{"begin":6318,"end":6328},"obj":"Body_part"},{"id":"T108","span":{"begin":6323,"end":6328},"obj":"Body_part"},{"id":"T109","span":{"begin":6411,"end":6413},"obj":"Body_part"}],"attributes":[{"id":"A53","pred":"fma_id","subj":"T53","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A54","pred":"fma_id","subj":"T54","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A55","pred":"fma_id","subj":"T55","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A56","pred":"fma_id","subj":"T56","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A57","pred":"fma_id","subj":"T57","obj":"http://purl.org/sig/ont/fma/fma323134"},{"id":"A58","pred":"fma_id","subj":"T58","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A59","pred":"fma_id","subj":"T59","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A60","pred":"fma_id","subj":"T60","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A61","pred":"fma_id","subj":"T61","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A62","pred":"fma_id","subj":"T62","obj":"http://purl.org/sig/ont/fma/fma55631"},{"id":"A63","pred":"fma_id","subj":"T63","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A64","pred":"fma_id","subj":"T64","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A65","pred":"fma_id","subj":"T65","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A66","pred":"fma_id","subj":"T66","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A67","pred":"fma_id","subj":"T67","obj":"http://purl.org/sig/ont/fma/fma85541"},{"id":"A68","pred":"fma_id","subj":"T68","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A69","pred":"fma_id","subj":"T69","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A70","pred":"fma_id","subj":"T70","obj":"http://purl.org/sig/ont/fma/fma85541"},{"id":"A71","pred":"fma_id","subj":"T71","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A72","pred":"fma_id","subj":"T72","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A73","pred":"fma_id","subj":"T73","obj":"http://purl.org/sig/ont/fma/fma55631"},{"id":"A74","pred":"fma_id","subj":"T74","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma63368"},{"id":"A76","pred":"fma_id","subj":"T76","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A77","pred":"fma_id","subj":"T77","obj":"http://purl.org/sig/ont/fma/fma85541"},{"id":"A78","pred":"fma_id","subj":"T78","obj":"http://purl.org/sig/ont/fma/fma9608"},{"id":"A79","pred":"fma_id","subj":"T79","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A80","pred":"fma_id","subj":"T80","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A81","pred":"fma_id","subj":"T81","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A82","pred":"fma_id","subj":"T82","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A83","pred":"fma_id","subj":"T83","obj":"http://purl.org/sig/ont/fma/fma85541"},{"id":"A84","pred":"fma_id","subj":"T84","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A85","pred":"fma_id","subj":"T85","obj":"http://purl.org/sig/ont/fma/fma63368"},{"id":"A86","pred":"fma_id","subj":"T86","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A87","pred":"fma_id","subj":"T87","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A88","pred":"fma_id","subj":"T88","obj":"http://purl.org/sig/ont/fma/fma20110"},{"id":"A89","pred":"fma_id","subj":"T89","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A90","pred":"fma_id","subj":"T90","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A91","pred":"fma_id","subj":"T91","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A92","pred":"fma_id","subj":"T92","obj":"http://purl.org/sig/ont/fma/fma70546"},{"id":"A93","pred":"fma_id","subj":"T93","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A94","pred":"fma_id","subj":"T94","obj":"http://purl.org/sig/ont/fma/fma85541"},{"id":"A95","pred":"fma_id","subj":"T95","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A96","pred":"fma_id","subj":"T96","obj":"http://purl.org/sig/ont/fma/fma85541"},{"id":"A97","pred":"fma_id","subj":"T97","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A98","pred":"fma_id","subj":"T98","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A99","pred":"fma_id","subj":"T99","obj":"http://purl.org/sig/ont/fma/fma85541"},{"id":"A100","pred":"fma_id","subj":"T100","obj":"http://purl.org/sig/ont/fma/fma85541"},{"id":"A101","pred":"fma_id","subj":"T101","obj":"http://purl.org/sig/ont/fma/fma85541"},{"id":"A102","pred":"fma_id","subj":"T102","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A103","pred":"fma_id","subj":"T103","obj":"http://purl.org/sig/ont/fma/fma85541"},{"id":"A104","pred":"fma_id","subj":"T104","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A105","pred":"fma_id","subj":"T105","obj":"http://purl.org/sig/ont/fma/fma85541"},{"id":"A106","pred":"fma_id","subj":"T106","obj":"http://purl.org/sig/ont/fma/fma85541"},{"id":"A107","pred":"fma_id","subj":"T107","obj":"http://purl.org/sig/ont/fma/fma63368"},{"id":"A108","pred":"fma_id","subj":"T108","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A109","pred":"fma_id","subj":"T109","obj":"http://purl.org/sig/ont/fma/fma85541"}],"text":"Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020\nS.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country\n1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020\nDOC: June 2020 Both 18 Yrs. and older Brazil\n2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020\nDOC:September 2020 Both 18 Yrs. and older Jordan\n3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020\nDOC: July 2020 Both 18 to75 Yrs. China\n4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020\nDOC: July 2021 Both 18 to75 Yrs. –\n5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020\nDOC: December 2021 Both 18 to70 Yrs. China\n6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020\nDOC: February 2022 Both 18 to 65 Yrs. China\n7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs\n(MSCs-Exo) DOS: February 2020\nDOC: July 2020 Both 18 to75 Yrs. –\n8- NCT043\n36,254 Safety and Efficacy\nStudy of Allogeneic\nHuman Dental Pulp\nMesenchymal Stem\nCells to Treat Severe\nCOVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020\nDOC: March\n2021 Both 18 to 65 Yrs. China\n9- NCT043\n39,660 Clinical Research of Human Mesenchymal\nStem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020\nDOC: June 2020 Both 18 to 75 Yrs. China\n10- NCT043\n46,368 Bone Marrow-Derived\nMesenchymal Stem\nCell Treatment for\nSevere Patients With\nCoronavirus Disease\n2019 (COVID19) I and II Not\nRecruiting 20 BM-MSCs DOS: April 2020\nDOC: December\n2020 Both 18 to 75 Yrs. China\n11- NCT043\n52,803 Adipose Mesenchymal\nCells for Abatement of\nSARS CoV-2\nRespiratory\nCompromise in\nCOVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020\nDOC: April 2026 Both 18 to 90 Yrs. –\n12- NCT043\n49,631 A Clinical Trial to\nDetermine the Safety\nand Efficacy of Hope\nBiosciences\nAutologous\nMesenchymal Stem\nCell Therapy (HBadMSCs)\nto Provide\nProtection Against\nCOVID19 II Enrolling by\ninvitation 56 AD-MSCs DOS: May 2020\nDOC: December 2020 Both Child, Adult,\nOlder\nAdult United States\n13- NCT030\n42,143 Repair of Acute\nRespiratory Distress\nSyndrome by Stromal\nCell Administration\n(REALIST) (COVID19)\n(REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019\nDOC: October 2022 Both 16 Yrs. and older United Kingdom\n14- NCT043\n90,152 Safety and Efficacy of Intravenous Wharton’s\nJelly Derived\nMesenchymal Stem\nCells in Acute\nRespiratory Distress\nSyndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020\nDOC: May 2021 Both 18 to 80 Yrs. Colombia\n15- NCT043\n82,547 Treatment of\nCOVID19 Associated\nPneumonia with\nAllogenic Pooled\nOlfactory Mucosaderived\nMesenchymal\nStem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020\nDOC: June 2021 Both 18 to70 Yrs. Belarus\n16- NCT043\n66,323 Clinical Trial to Assess\nthe Safety and\nEfficacy of Intravenous\nAdministration of Allogeneic Adult\nMesenchymal Stem\nCells of Expanded\nAdipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020\nDOC: October 2021 Both 18 to 80 Yrs. –\n17- NCT043\n66,063 Mesenchymal Stem\nCell Therapy for SARS-CoV-2-related\nAcute Respiratory\nDistress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020\nDOC: December 2020 Both 18 to 65 Yrs. Iran\n18- NCT043\n77,334 Mesenchymal Stem\nCells (MSCs) in Inflammation-\nResolution Programs\nof Coronavirus\nDisease 2019\n(COVID19) Induced\nAcute Respiratory\nDistress Syndrome\n(ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020\nDOC: February 2021 Both 18 Yrs. and older Germany\n19- NCT043\n71,393 MSCs in COVID19\nARDS III Recruiting 300 MSCs\nRemestemcel-L DOS: April 30, 2020\nDOC: April 2022 Both 18 Yrs. and older United States\n20- NCT043\n62,189 Efficacy and Safety\nStudy of Allogeneic\nHB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020\nDOC: October 2020 Both Child,\nAdult,\nOlder\nAdult United States\n21- NCT043\n66,271 Clinical Trial of\nAllogeneic\nMesenchymal Cells\nfrom Umbilical Cord\nTissue in Patients with\nCOVID19 II Recruiting 106 UC-MSCs DOS: May 2020\nDOC: May 2021 Both 40 to 80 Yrs. Spain\n22- NCT043\n48,435 A Randomized,\nDouble-Blind,\nPlacebo-Controlled\nClinical Trial to Determine the Safety and Efficacy of Hope\nBiosciences\nAllogeneic\nMesenchymal Stem\nCell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020\nDOC: April 2021 Both Child,\nAdult, Older\nAdult United States\n23- NCT043\n71,601 Safety and Effectiveness of Mesenchymal Stem\nCells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020\nDOC: December 2022 Both 18 to 70 Yrs. China\n24- NCT043\n55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020\nDOC: May 2021 Both 18 Yrs. and older United States\n25- NCT043\n92,778 Clinical Use of Stem\nCells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020\nDOC: September 2020 Both 40 to 60 Yrs. Turkey\n26- NCT043\n97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020\nDOC: June 2021 Both 18 to 80 Yrs. –\n27- NCT043\n90,139 Efficacy and Safety\nEvaluation of Mesenchymal Stem\nCells for the Treatment of Patients\nwith Respiratory\nDistress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020\nDOC: December 2020 Both 18 to 75 Yrs. Spain\n28- NCT042\n69,525 Umbilical Cord (UC)- Derived Mesenchymal\nStem Cells (MSCs)\nTreatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020\nDOC: September 2020 Both 18 to 75 Yrs. China"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T14","span":{"begin":925,"end":936},"obj":"Body_part"},{"id":"T15","span":{"begin":1267,"end":1281},"obj":"Body_part"},{"id":"T16","span":{"begin":1380,"end":1382},"obj":"Body_part"},{"id":"T17","span":{"begin":1757,"end":1768},"obj":"Body_part"},{"id":"T18","span":{"begin":2039,"end":2041},"obj":"Body_part"},{"id":"T19","span":{"begin":2124,"end":2135},"obj":"Body_part"},{"id":"T20","span":{"begin":2973,"end":2975},"obj":"Body_part"},{"id":"T21","span":{"begin":3695,"end":3709},"obj":"Body_part"},{"id":"T22","span":{"begin":4779,"end":4793},"obj":"Body_part"},{"id":"T23","span":{"begin":4794,"end":4800},"obj":"Body_part"},{"id":"T24","span":{"begin":4844,"end":4846},"obj":"Body_part"},{"id":"T25","span":{"begin":5414,"end":5416},"obj":"Body_part"},{"id":"T26","span":{"begin":5507,"end":5509},"obj":"Body_part"},{"id":"T27","span":{"begin":5559,"end":5561},"obj":"Body_part"},{"id":"T28","span":{"begin":5731,"end":5733},"obj":"Body_part"},{"id":"T29","span":{"begin":6277,"end":6291},"obj":"Body_part"},{"id":"T30","span":{"begin":6293,"end":6295},"obj":"Body_part"},{"id":"T31","span":{"begin":6411,"end":6413},"obj":"Body_part"}],"attributes":[{"id":"A14","pred":"uberon_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/UBERON_0001754"},{"id":"A15","pred":"uberon_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"A16","pred":"uberon_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"A17","pred":"uberon_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/UBERON_0001754"},{"id":"A18","pred":"uberon_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"A19","pred":"uberon_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/UBERON_0002371"},{"id":"A20","pred":"uberon_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"A21","pred":"uberon_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/UBERON_0001013"},{"id":"A22","pred":"uberon_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"A23","pred":"uberon_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"A24","pred":"uberon_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"A25","pred":"uberon_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"A27","pred":"uberon_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"A28","pred":"uberon_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"A29","pred":"uberon_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"A30","pred":"uberon_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"A31","pred":"uberon_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/UBERON_0002331"}],"text":"Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020\nS.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country\n1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020\nDOC: June 2020 Both 18 Yrs. and older Brazil\n2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020\nDOC:September 2020 Both 18 Yrs. and older Jordan\n3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020\nDOC: July 2020 Both 18 to75 Yrs. China\n4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020\nDOC: July 2021 Both 18 to75 Yrs. –\n5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020\nDOC: December 2021 Both 18 to70 Yrs. China\n6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020\nDOC: February 2022 Both 18 to 65 Yrs. China\n7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs\n(MSCs-Exo) DOS: February 2020\nDOC: July 2020 Both 18 to75 Yrs. –\n8- NCT043\n36,254 Safety and Efficacy\nStudy of Allogeneic\nHuman Dental Pulp\nMesenchymal Stem\nCells to Treat Severe\nCOVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020\nDOC: March\n2021 Both 18 to 65 Yrs. China\n9- NCT043\n39,660 Clinical Research of Human Mesenchymal\nStem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020\nDOC: June 2020 Both 18 to 75 Yrs. China\n10- NCT043\n46,368 Bone Marrow-Derived\nMesenchymal Stem\nCell Treatment for\nSevere Patients With\nCoronavirus Disease\n2019 (COVID19) I and II Not\nRecruiting 20 BM-MSCs DOS: April 2020\nDOC: December\n2020 Both 18 to 75 Yrs. China\n11- NCT043\n52,803 Adipose Mesenchymal\nCells for Abatement of\nSARS CoV-2\nRespiratory\nCompromise in\nCOVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020\nDOC: April 2026 Both 18 to 90 Yrs. –\n12- NCT043\n49,631 A Clinical Trial to\nDetermine the Safety\nand Efficacy of Hope\nBiosciences\nAutologous\nMesenchymal Stem\nCell Therapy (HBadMSCs)\nto Provide\nProtection Against\nCOVID19 II Enrolling by\ninvitation 56 AD-MSCs DOS: May 2020\nDOC: December 2020 Both Child, Adult,\nOlder\nAdult United States\n13- NCT030\n42,143 Repair of Acute\nRespiratory Distress\nSyndrome by Stromal\nCell Administration\n(REALIST) (COVID19)\n(REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019\nDOC: October 2022 Both 16 Yrs. and older United Kingdom\n14- NCT043\n90,152 Safety and Efficacy of Intravenous Wharton’s\nJelly Derived\nMesenchymal Stem\nCells in Acute\nRespiratory Distress\nSyndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020\nDOC: May 2021 Both 18 to 80 Yrs. Colombia\n15- NCT043\n82,547 Treatment of\nCOVID19 Associated\nPneumonia with\nAllogenic Pooled\nOlfactory Mucosaderived\nMesenchymal\nStem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020\nDOC: June 2021 Both 18 to70 Yrs. Belarus\n16- NCT043\n66,323 Clinical Trial to Assess\nthe Safety and\nEfficacy of Intravenous\nAdministration of Allogeneic Adult\nMesenchymal Stem\nCells of Expanded\nAdipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020\nDOC: October 2021 Both 18 to 80 Yrs. –\n17- NCT043\n66,063 Mesenchymal Stem\nCell Therapy for SARS-CoV-2-related\nAcute Respiratory\nDistress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020\nDOC: December 2020 Both 18 to 65 Yrs. Iran\n18- NCT043\n77,334 Mesenchymal Stem\nCells (MSCs) in Inflammation-\nResolution Programs\nof Coronavirus\nDisease 2019\n(COVID19) Induced\nAcute Respiratory\nDistress Syndrome\n(ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020\nDOC: February 2021 Both 18 Yrs. and older Germany\n19- NCT043\n71,393 MSCs in COVID19\nARDS III Recruiting 300 MSCs\nRemestemcel-L DOS: April 30, 2020\nDOC: April 2022 Both 18 Yrs. and older United States\n20- NCT043\n62,189 Efficacy and Safety\nStudy of Allogeneic\nHB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020\nDOC: October 2020 Both Child,\nAdult,\nOlder\nAdult United States\n21- NCT043\n66,271 Clinical Trial of\nAllogeneic\nMesenchymal Cells\nfrom Umbilical Cord\nTissue in Patients with\nCOVID19 II Recruiting 106 UC-MSCs DOS: May 2020\nDOC: May 2021 Both 40 to 80 Yrs. Spain\n22- NCT043\n48,435 A Randomized,\nDouble-Blind,\nPlacebo-Controlled\nClinical Trial to Determine the Safety and Efficacy of Hope\nBiosciences\nAllogeneic\nMesenchymal Stem\nCell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020\nDOC: April 2021 Both Child,\nAdult, Older\nAdult United States\n23- NCT043\n71,601 Safety and Effectiveness of Mesenchymal Stem\nCells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020\nDOC: December 2022 Both 18 to 70 Yrs. China\n24- NCT043\n55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020\nDOC: May 2021 Both 18 Yrs. and older United States\n25- NCT043\n92,778 Clinical Use of Stem\nCells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020\nDOC: September 2020 Both 40 to 60 Yrs. Turkey\n26- NCT043\n97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020\nDOC: June 2021 Both 18 to 80 Yrs. –\n27- NCT043\n90,139 Efficacy and Safety\nEvaluation of Mesenchymal Stem\nCells for the Treatment of Patients\nwith Respiratory\nDistress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020\nDOC: December 2020 Both 18 to 75 Yrs. Spain\n28- NCT042\n69,525 Umbilical Cord (UC)- Derived Mesenchymal\nStem Cells (MSCs)\nTreatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020\nDOC: September 2020 Both 18 to 75 Yrs. China"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T43","span":{"begin":60,"end":67},"obj":"Disease"},{"id":"T44","span":{"begin":388,"end":395},"obj":"Disease"},{"id":"T45","span":{"begin":396,"end":405},"obj":"Disease"},{"id":"T46","span":{"begin":527,"end":534},"obj":"Disease"},{"id":"T47","span":{"begin":770,"end":777},"obj":"Disease"},{"id":"T48","span":{"begin":904,"end":913},"obj":"Disease"},{"id":"T49","span":{"begin":1099,"end":1108},"obj":"Disease"},{"id":"T50","span":{"begin":1350,"end":1359},"obj":"Disease"},{"id":"T51","span":{"begin":1569,"end":1578},"obj":"Disease"},{"id":"T52","span":{"begin":1621,"end":1623},"obj":"Disease"},{"id":"T53","span":{"begin":1808,"end":1815},"obj":"Disease"},{"id":"T54","span":{"begin":1998,"end":2005},"obj":"Disease"},{"id":"T55","span":{"begin":2006,"end":2015},"obj":"Disease"},{"id":"T56","span":{"begin":2227,"end":2234},"obj":"Disease"},{"id":"T57","span":{"begin":2392,"end":2396},"obj":"Disease"},{"id":"T58","span":{"begin":2429,"end":2437},"obj":"Disease"},{"id":"T59","span":{"begin":2466,"end":2468},"obj":"Disease"},{"id":"T60","span":{"begin":2701,"end":2708},"obj":"Disease"},{"id":"T61","span":{"begin":2739,"end":2741},"obj":"Disease"},{"id":"T62","span":{"begin":2931,"end":2938},"obj":"Disease"},{"id":"T63","span":{"begin":3224,"end":3231},"obj":"Disease"},{"id":"T64","span":{"begin":3355,"end":3362},"obj":"Disease"},{"id":"T65","span":{"begin":3374,"end":3383},"obj":"Disease"},{"id":"T66","span":{"begin":3734,"end":3743},"obj":"Disease"},{"id":"T67","span":{"begin":3751,"end":3758},"obj":"Disease"},{"id":"T68","span":{"begin":3786,"end":3788},"obj":"Disease"},{"id":"T69","span":{"begin":3901,"end":3909},"obj":"Disease"},{"id":"T70","span":{"begin":4136,"end":4151},"obj":"Disease"},{"id":"T71","span":{"begin":4202,"end":4209},"obj":"Disease"},{"id":"T72","span":{"begin":4256,"end":4260},"obj":"Disease"},{"id":"T73","span":{"begin":4381,"end":4388},"obj":"Disease"},{"id":"T74","span":{"begin":4389,"end":4393},"obj":"Disease"},{"id":"T75","span":{"begin":4594,"end":4601},"obj":"Disease"},{"id":"T76","span":{"begin":4624,"end":4626},"obj":"Disease"},{"id":"T77","span":{"begin":4818,"end":4825},"obj":"Disease"},{"id":"T78","span":{"begin":5124,"end":5131},"obj":"Disease"},{"id":"T79","span":{"begin":5163,"end":5165},"obj":"Disease"},{"id":"T80","span":{"begin":5337,"end":5346},"obj":"Disease"},{"id":"T81","span":{"begin":5350,"end":5374},"obj":"Disease"},{"id":"T82","span":{"begin":5519,"end":5526},"obj":"Disease"},{"id":"T83","span":{"begin":5700,"end":5707},"obj":"Disease"},{"id":"T84","span":{"begin":5898,"end":5905},"obj":"Disease"},{"id":"T85","span":{"begin":5906,"end":5915},"obj":"Disease"},{"id":"T86","span":{"begin":6162,"end":6169},"obj":"Disease"},{"id":"T87","span":{"begin":6384,"end":6393},"obj":"Disease"}],"attributes":[{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A47","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A48","pred":"mondo_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A52","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A53","pred":"mondo_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A54","pred":"mondo_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A55","pred":"mondo_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A56","pred":"mondo_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A57","pred":"mondo_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A58","pred":"mondo_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A59","pred":"mondo_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A60","pred":"mondo_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A61","pred":"mondo_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A62","pred":"mondo_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A63","pred":"mondo_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A65","pred":"mondo_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A66","pred":"mondo_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A67","pred":"mondo_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A68","pred":"mondo_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A69","pred":"mondo_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A70","pred":"mondo_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A71","pred":"mondo_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A72","pred":"mondo_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A73","pred":"mondo_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A74","pred":"mondo_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A75","pred":"mondo_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A82","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A83","pred":"mondo_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A86","pred":"mondo_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A87","pred":"mondo_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020\nS.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country\n1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020\nDOC: June 2020 Both 18 Yrs. and older Brazil\n2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020\nDOC:September 2020 Both 18 Yrs. and older Jordan\n3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020\nDOC: July 2020 Both 18 to75 Yrs. China\n4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020\nDOC: July 2021 Both 18 to75 Yrs. –\n5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020\nDOC: December 2021 Both 18 to70 Yrs. China\n6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020\nDOC: February 2022 Both 18 to 65 Yrs. China\n7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs\n(MSCs-Exo) DOS: February 2020\nDOC: July 2020 Both 18 to75 Yrs. –\n8- NCT043\n36,254 Safety and Efficacy\nStudy of Allogeneic\nHuman Dental Pulp\nMesenchymal Stem\nCells to Treat Severe\nCOVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020\nDOC: March\n2021 Both 18 to 65 Yrs. China\n9- NCT043\n39,660 Clinical Research of Human Mesenchymal\nStem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020\nDOC: June 2020 Both 18 to 75 Yrs. China\n10- NCT043\n46,368 Bone Marrow-Derived\nMesenchymal Stem\nCell Treatment for\nSevere Patients With\nCoronavirus Disease\n2019 (COVID19) I and II Not\nRecruiting 20 BM-MSCs DOS: April 2020\nDOC: December\n2020 Both 18 to 75 Yrs. China\n11- NCT043\n52,803 Adipose Mesenchymal\nCells for Abatement of\nSARS CoV-2\nRespiratory\nCompromise in\nCOVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020\nDOC: April 2026 Both 18 to 90 Yrs. –\n12- NCT043\n49,631 A Clinical Trial to\nDetermine the Safety\nand Efficacy of Hope\nBiosciences\nAutologous\nMesenchymal Stem\nCell Therapy (HBadMSCs)\nto Provide\nProtection Against\nCOVID19 II Enrolling by\ninvitation 56 AD-MSCs DOS: May 2020\nDOC: December 2020 Both Child, Adult,\nOlder\nAdult United States\n13- NCT030\n42,143 Repair of Acute\nRespiratory Distress\nSyndrome by Stromal\nCell Administration\n(REALIST) (COVID19)\n(REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019\nDOC: October 2022 Both 16 Yrs. and older United Kingdom\n14- NCT043\n90,152 Safety and Efficacy of Intravenous Wharton’s\nJelly Derived\nMesenchymal Stem\nCells in Acute\nRespiratory Distress\nSyndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020\nDOC: May 2021 Both 18 to 80 Yrs. Colombia\n15- NCT043\n82,547 Treatment of\nCOVID19 Associated\nPneumonia with\nAllogenic Pooled\nOlfactory Mucosaderived\nMesenchymal\nStem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020\nDOC: June 2021 Both 18 to70 Yrs. Belarus\n16- NCT043\n66,323 Clinical Trial to Assess\nthe Safety and\nEfficacy of Intravenous\nAdministration of Allogeneic Adult\nMesenchymal Stem\nCells of Expanded\nAdipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020\nDOC: October 2021 Both 18 to 80 Yrs. –\n17- NCT043\n66,063 Mesenchymal Stem\nCell Therapy for SARS-CoV-2-related\nAcute Respiratory\nDistress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020\nDOC: December 2020 Both 18 to 65 Yrs. Iran\n18- NCT043\n77,334 Mesenchymal Stem\nCells (MSCs) in Inflammation-\nResolution Programs\nof Coronavirus\nDisease 2019\n(COVID19) Induced\nAcute Respiratory\nDistress Syndrome\n(ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020\nDOC: February 2021 Both 18 Yrs. and older Germany\n19- NCT043\n71,393 MSCs in COVID19\nARDS III Recruiting 300 MSCs\nRemestemcel-L DOS: April 30, 2020\nDOC: April 2022 Both 18 Yrs. and older United States\n20- NCT043\n62,189 Efficacy and Safety\nStudy of Allogeneic\nHB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020\nDOC: October 2020 Both Child,\nAdult,\nOlder\nAdult United States\n21- NCT043\n66,271 Clinical Trial of\nAllogeneic\nMesenchymal Cells\nfrom Umbilical Cord\nTissue in Patients with\nCOVID19 II Recruiting 106 UC-MSCs DOS: May 2020\nDOC: May 2021 Both 40 to 80 Yrs. Spain\n22- NCT043\n48,435 A Randomized,\nDouble-Blind,\nPlacebo-Controlled\nClinical Trial to Determine the Safety and Efficacy of Hope\nBiosciences\nAllogeneic\nMesenchymal Stem\nCell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020\nDOC: April 2021 Both Child,\nAdult, Older\nAdult United States\n23- NCT043\n71,601 Safety and Effectiveness of Mesenchymal Stem\nCells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020\nDOC: December 2022 Both 18 to 70 Yrs. China\n24- NCT043\n55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020\nDOC: May 2021 Both 18 Yrs. and older United States\n25- NCT043\n92,778 Clinical Use of Stem\nCells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020\nDOC: September 2020 Both 40 to 60 Yrs. Turkey\n26- NCT043\n97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020\nDOC: June 2021 Both 18 to 80 Yrs. –\n27- NCT043\n90,139 Efficacy and Safety\nEvaluation of Mesenchymal Stem\nCells for the Treatment of Patients\nwith Respiratory\nDistress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020\nDOC: December 2020 Both 18 to 75 Yrs. Spain\n28- NCT042\n69,525 Umbilical Cord (UC)- Derived Mesenchymal\nStem Cells (MSCs)\nTreatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020\nDOC: September 2020 Both 18 to 75 Yrs. China"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T86","span":{"begin":279,"end":283},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T87","span":{"begin":279,"end":283},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T88","span":{"begin":284,"end":290},"obj":"http://purl.obolibrary.org/obo/UBERON_0003100"},{"id":"T89","span":{"begin":330,"end":334},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T90","span":{"begin":336,"end":357},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T91","span":{"begin":431,"end":435},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T92","span":{"begin":474,"end":476},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T93","span":{"begin":567,"end":589},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T94","span":{"begin":653,"end":655},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T95","span":{"begin":708,"end":730},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T96","span":{"begin":749,"end":754},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T97","span":{"begin":837,"end":839},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T98","span":{"begin":937,"end":959},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T99","span":{"begin":1033,"end":1035},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T100","span":{"begin":1063,"end":1084},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T101","span":{"begin":1218,"end":1220},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T102","span":{"begin":1261,"end":1266},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T103","span":{"begin":1267,"end":1281},"obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"T104","span":{"begin":1267,"end":1281},"obj":"http://www.ebi.ac.uk/efo/EFO_0001415"},{"id":"T105","span":{"begin":1282,"end":1304},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T106","span":{"begin":1377,"end":1379},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T107","span":{"begin":1380,"end":1382},"obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"T108","span":{"begin":1428,"end":1430},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T109","span":{"begin":1463,"end":1464},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T110","span":{"begin":1503,"end":1525},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T111","span":{"begin":1679,"end":1681},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T112","span":{"begin":1751,"end":1756},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T113","span":{"begin":1786,"end":1791},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T114","span":{"begin":1891,"end":1893},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T115","span":{"begin":1949,"end":1954},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T116","span":{"begin":1967,"end":1977},"obj":"http://purl.obolibrary.org/obo/CL_0000034"},{"id":"T117","span":{"begin":2039,"end":2041},"obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"T118","span":{"begin":2086,"end":2088},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T119","span":{"begin":2124,"end":2128},"obj":"http://purl.obolibrary.org/obo/UBERON_0002481"},{"id":"T120","span":{"begin":2161,"end":2165},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T121","span":{"begin":2263,"end":2265},"obj":"http://purl.obolibrary.org/obo/CLO_0001997"},{"id":"T122","span":{"begin":2311,"end":2313},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T123","span":{"begin":2331,"end":2333},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T124","span":{"begin":2349,"end":2356},"obj":"http://purl.obolibrary.org/obo/UBERON_0001013"},{"id":"T125","span":{"begin":2369,"end":2374},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T126","span":{"begin":2511,"end":2513},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T127","span":{"begin":2545,"end":2546},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T128","span":{"begin":2647,"end":2651},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T129","span":{"begin":2900,"end":2904},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T130","span":{"begin":2973,"end":2975},"obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"T131","span":{"begin":3172,"end":3177},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T132","span":{"begin":3301,"end":3303},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T133","span":{"begin":3442,"end":3452},"obj":"http://purl.obolibrary.org/obo/CL_0000034"},{"id":"T134","span":{"begin":3522,"end":3524},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T135","span":{"begin":3677,"end":3682},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T136","span":{"begin":3695,"end":3709},"obj":"http://purl.obolibrary.org/obo/UBERON_0001013"},{"id":"T137","span":{"begin":3833,"end":3835},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T138","span":{"begin":3884,"end":3888},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T139","span":{"begin":4069,"end":4071},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T140","span":{"begin":4088,"end":4090},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T141","span":{"begin":4123,"end":4128},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T142","span":{"begin":4283,"end":4285},"obj":"http://purl.obolibrary.org/obo/CLO_0001997"},{"id":"T143","span":{"begin":4329,"end":4331},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T144","span":{"begin":4473,"end":4475},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T145","span":{"begin":4563,"end":4565},"obj":"http://purl.obolibrary.org/obo/CLO_0003622"},{"id":"T146","span":{"begin":4768,"end":4773},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T147","span":{"begin":4779,"end":4793},"obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"T148","span":{"begin":4779,"end":4793},"obj":"http://www.ebi.ac.uk/efo/EFO_0001415"},{"id":"T149","span":{"begin":4844,"end":4846},"obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"T150","span":{"begin":4905,"end":4907},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T151","span":{"begin":4923,"end":4924},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T152","span":{"begin":5070,"end":5074},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T153","span":{"begin":5311,"end":5316},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T154","span":{"begin":5389,"end":5395},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T155","span":{"begin":5414,"end":5416},"obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"T156","span":{"begin":5462,"end":5464},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T157","span":{"begin":5507,"end":5509},"obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"T158","span":{"begin":5559,"end":5561},"obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"T159","span":{"begin":5602,"end":5604},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T160","span":{"begin":5673,"end":5678},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T161","span":{"begin":5731,"end":5733},"obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"T162","span":{"begin":5794,"end":5800},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9005"},{"id":"T163","span":{"begin":5966,"end":5968},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T164","span":{"begin":5969,"end":5971},"obj":"http://purl.obolibrary.org/obo/CLO_0001997"},{"id":"T165","span":{"begin":6012,"end":6014},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T166","span":{"begin":6028,"end":6030},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T167","span":{"begin":6097,"end":6102},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T168","span":{"begin":6239,"end":6241},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T169","span":{"begin":6277,"end":6291},"obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"T170","span":{"begin":6277,"end":6291},"obj":"http://www.ebi.ac.uk/efo/EFO_0001415"},{"id":"T171","span":{"begin":6293,"end":6295},"obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"T172","span":{"begin":6318,"end":6328},"obj":"http://purl.obolibrary.org/obo/CL_0000034"},{"id":"T173","span":{"begin":6411,"end":6413},"obj":"http://purl.obolibrary.org/obo/UBERON_0002331"},{"id":"T174","span":{"begin":6463,"end":6465},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"}],"text":"Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020\nS.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country\n1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020\nDOC: June 2020 Both 18 Yrs. and older Brazil\n2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020\nDOC:September 2020 Both 18 Yrs. and older Jordan\n3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020\nDOC: July 2020 Both 18 to75 Yrs. China\n4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020\nDOC: July 2021 Both 18 to75 Yrs. –\n5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020\nDOC: December 2021 Both 18 to70 Yrs. China\n6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020\nDOC: February 2022 Both 18 to 65 Yrs. China\n7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs\n(MSCs-Exo) DOS: February 2020\nDOC: July 2020 Both 18 to75 Yrs. –\n8- NCT043\n36,254 Safety and Efficacy\nStudy of Allogeneic\nHuman Dental Pulp\nMesenchymal Stem\nCells to Treat Severe\nCOVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020\nDOC: March\n2021 Both 18 to 65 Yrs. China\n9- NCT043\n39,660 Clinical Research of Human Mesenchymal\nStem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020\nDOC: June 2020 Both 18 to 75 Yrs. China\n10- NCT043\n46,368 Bone Marrow-Derived\nMesenchymal Stem\nCell Treatment for\nSevere Patients With\nCoronavirus Disease\n2019 (COVID19) I and II Not\nRecruiting 20 BM-MSCs DOS: April 2020\nDOC: December\n2020 Both 18 to 75 Yrs. China\n11- NCT043\n52,803 Adipose Mesenchymal\nCells for Abatement of\nSARS CoV-2\nRespiratory\nCompromise in\nCOVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020\nDOC: April 2026 Both 18 to 90 Yrs. –\n12- NCT043\n49,631 A Clinical Trial to\nDetermine the Safety\nand Efficacy of Hope\nBiosciences\nAutologous\nMesenchymal Stem\nCell Therapy (HBadMSCs)\nto Provide\nProtection Against\nCOVID19 II Enrolling by\ninvitation 56 AD-MSCs DOS: May 2020\nDOC: December 2020 Both Child, Adult,\nOlder\nAdult United States\n13- NCT030\n42,143 Repair of Acute\nRespiratory Distress\nSyndrome by Stromal\nCell Administration\n(REALIST) (COVID19)\n(REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019\nDOC: October 2022 Both 16 Yrs. and older United Kingdom\n14- NCT043\n90,152 Safety and Efficacy of Intravenous Wharton’s\nJelly Derived\nMesenchymal Stem\nCells in Acute\nRespiratory Distress\nSyndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020\nDOC: May 2021 Both 18 to 80 Yrs. Colombia\n15- NCT043\n82,547 Treatment of\nCOVID19 Associated\nPneumonia with\nAllogenic Pooled\nOlfactory Mucosaderived\nMesenchymal\nStem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020\nDOC: June 2021 Both 18 to70 Yrs. Belarus\n16- NCT043\n66,323 Clinical Trial to Assess\nthe Safety and\nEfficacy of Intravenous\nAdministration of Allogeneic Adult\nMesenchymal Stem\nCells of Expanded\nAdipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020\nDOC: October 2021 Both 18 to 80 Yrs. –\n17- NCT043\n66,063 Mesenchymal Stem\nCell Therapy for SARS-CoV-2-related\nAcute Respiratory\nDistress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020\nDOC: December 2020 Both 18 to 65 Yrs. Iran\n18- NCT043\n77,334 Mesenchymal Stem\nCells (MSCs) in Inflammation-\nResolution Programs\nof Coronavirus\nDisease 2019\n(COVID19) Induced\nAcute Respiratory\nDistress Syndrome\n(ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020\nDOC: February 2021 Both 18 Yrs. and older Germany\n19- NCT043\n71,393 MSCs in COVID19\nARDS III Recruiting 300 MSCs\nRemestemcel-L DOS: April 30, 2020\nDOC: April 2022 Both 18 Yrs. and older United States\n20- NCT043\n62,189 Efficacy and Safety\nStudy of Allogeneic\nHB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020\nDOC: October 2020 Both Child,\nAdult,\nOlder\nAdult United States\n21- NCT043\n66,271 Clinical Trial of\nAllogeneic\nMesenchymal Cells\nfrom Umbilical Cord\nTissue in Patients with\nCOVID19 II Recruiting 106 UC-MSCs DOS: May 2020\nDOC: May 2021 Both 40 to 80 Yrs. Spain\n22- NCT043\n48,435 A Randomized,\nDouble-Blind,\nPlacebo-Controlled\nClinical Trial to Determine the Safety and Efficacy of Hope\nBiosciences\nAllogeneic\nMesenchymal Stem\nCell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020\nDOC: April 2021 Both Child,\nAdult, Older\nAdult United States\n23- NCT043\n71,601 Safety and Effectiveness of Mesenchymal Stem\nCells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020\nDOC: December 2022 Both 18 to 70 Yrs. China\n24- NCT043\n55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020\nDOC: May 2021 Both 18 Yrs. and older United States\n25- NCT043\n92,778 Clinical Use of Stem\nCells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020\nDOC: September 2020 Both 40 to 60 Yrs. Turkey\n26- NCT043\n97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020\nDOC: June 2021 Both 18 to 80 Yrs. –\n27- NCT043\n90,139 Efficacy and Safety\nEvaluation of Mesenchymal Stem\nCells for the Treatment of Patients\nwith Respiratory\nDistress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020\nDOC: December 2020 Both 18 to 75 Yrs. Spain\n28- NCT042\n69,525 Umbilical Cord (UC)- Derived Mesenchymal\nStem Cells (MSCs)\nTreatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020\nDOC: September 2020 Both 18 to 75 Yrs. China"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T24","span":{"begin":267,"end":270},"obj":"Chemical"},{"id":"T25","span":{"begin":454,"end":457},"obj":"Chemical"},{"id":"T26","span":{"begin":779,"end":781},"obj":"Chemical"},{"id":"T27","span":{"begin":817,"end":820},"obj":"Chemical"},{"id":"T28","span":{"begin":1013,"end":1016},"obj":"Chemical"},{"id":"T29","span":{"begin":1194,"end":1197},"obj":"Chemical"},{"id":"T30","span":{"begin":1404,"end":1407},"obj":"Chemical"},{"id":"T31","span":{"begin":1621,"end":1623},"obj":"Chemical"},{"id":"T32","span":{"begin":1659,"end":1662},"obj":"Chemical"},{"id":"T33","span":{"begin":1831,"end":1833},"obj":"Chemical"},{"id":"T34","span":{"begin":1870,"end":1873},"obj":"Chemical"},{"id":"T35","span":{"begin":2022,"end":2024},"obj":"Chemical"},{"id":"T36","span":{"begin":2066,"end":2069},"obj":"Chemical"},{"id":"T37","span":{"begin":2242,"end":2244},"obj":"Chemical"},{"id":"T38","span":{"begin":2287,"end":2290},"obj":"Chemical"},{"id":"T39","span":{"begin":2466,"end":2468},"obj":"Chemical"},{"id":"T40","span":{"begin":2490,"end":2493},"obj":"Chemical"},{"id":"T41","span":{"begin":2709,"end":2711},"obj":"Chemical"},{"id":"T42","span":{"begin":2739,"end":2741},"obj":"Chemical"},{"id":"T43","span":{"begin":2761,"end":2764},"obj":"Chemical"},{"id":"T44","span":{"begin":2956,"end":2958},"obj":"Chemical"},{"id":"T45","span":{"begin":3022,"end":3025},"obj":"Chemical"},{"id":"T46","span":{"begin":3238,"end":3240},"obj":"Chemical"},{"id":"T47","span":{"begin":3282,"end":3285},"obj":"Chemical"},{"id":"T48","span":{"begin":3459,"end":3461},"obj":"Chemical"},{"id":"T49","span":{"begin":3502,"end":3505},"obj":"Chemical"},{"id":"T50","span":{"begin":3765,"end":3767},"obj":"Chemical"},{"id":"T51","span":{"begin":3786,"end":3788},"obj":"Chemical"},{"id":"T52","span":{"begin":3810,"end":3813},"obj":"Chemical"},{"id":"T53","span":{"begin":3956,"end":3958},"obj":"Chemical"},{"id":"T54","span":{"begin":4045,"end":4048},"obj":"Chemical"},{"id":"T55","span":{"begin":4262,"end":4264},"obj":"Chemical"},{"id":"T56","span":{"begin":4305,"end":4308},"obj":"Chemical"},{"id":"T57","span":{"begin":4452,"end":4455},"obj":"Chemical"},{"id":"T58","span":{"begin":4602,"end":4604},"obj":"Chemical"},{"id":"T59","span":{"begin":4624,"end":4626},"obj":"Chemical"},{"id":"T60","span":{"begin":4646,"end":4649},"obj":"Chemical"},{"id":"T61","span":{"begin":4826,"end":4828},"obj":"Chemical"},{"id":"T62","span":{"begin":4866,"end":4869},"obj":"Chemical"},{"id":"T63","span":{"begin":5132,"end":5134},"obj":"Chemical"},{"id":"T64","span":{"begin":5163,"end":5165},"obj":"Chemical"},{"id":"T65","span":{"begin":5187,"end":5190},"obj":"Chemical"},{"id":"T66","span":{"begin":5438,"end":5441},"obj":"Chemical"},{"id":"T67","span":{"begin":5542,"end":5544},"obj":"Chemical"},{"id":"T68","span":{"begin":5583,"end":5586},"obj":"Chemical"},{"id":"T69","span":{"begin":5714,"end":5716},"obj":"Chemical"},{"id":"T70","span":{"begin":5755,"end":5758},"obj":"Chemical"},{"id":"T71","span":{"begin":5992,"end":5995},"obj":"Chemical"},{"id":"T72","span":{"begin":6176,"end":6178},"obj":"Chemical"},{"id":"T73","span":{"begin":6215,"end":6218},"obj":"Chemical"},{"id":"T74","span":{"begin":6394,"end":6396},"obj":"Chemical"},{"id":"T75","span":{"begin":6438,"end":6441},"obj":"Chemical"}],"attributes":[{"id":"A24","pred":"chebi_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A27","pred":"chebi_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A28","pred":"chebi_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A29","pred":"chebi_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A30","pred":"chebi_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A31","pred":"chebi_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_73803"},{"id":"A32","pred":"chebi_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A33","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A34","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A35","pred":"chebi_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A38","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A39","pred":"chebi_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/CHEBI_73803"},{"id":"A40","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A41","pred":"chebi_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A42","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_73803"},{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A44","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A45","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A46","pred":"chebi_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A48","pred":"chebi_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A51","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_73803"},{"id":"A52","pred":"chebi_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A55","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A56","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A57","pred":"chebi_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A58","pred":"chebi_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A59","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_73803"},{"id":"A60","pred":"chebi_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A61","pred":"chebi_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A62","pred":"chebi_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A63","pred":"chebi_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A64","pred":"chebi_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/CHEBI_73803"},{"id":"A65","pred":"chebi_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A66","pred":"chebi_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A67","pred":"chebi_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A68","pred":"chebi_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A69","pred":"chebi_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A70","pred":"chebi_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A71","pred":"chebi_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A72","pred":"chebi_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A73","pred":"chebi_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"},{"id":"A74","pred":"chebi_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A75","pred":"chebi_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/CHEBI_16973"}],"text":"Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020\nS.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country\n1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020\nDOC: June 2020 Both 18 Yrs. and older Brazil\n2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020\nDOC:September 2020 Both 18 Yrs. and older Jordan\n3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020\nDOC: July 2020 Both 18 to75 Yrs. China\n4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020\nDOC: July 2021 Both 18 to75 Yrs. –\n5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020\nDOC: December 2021 Both 18 to70 Yrs. China\n6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020\nDOC: February 2022 Both 18 to 65 Yrs. China\n7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs\n(MSCs-Exo) DOS: February 2020\nDOC: July 2020 Both 18 to75 Yrs. –\n8- NCT043\n36,254 Safety and Efficacy\nStudy of Allogeneic\nHuman Dental Pulp\nMesenchymal Stem\nCells to Treat Severe\nCOVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020\nDOC: March\n2021 Both 18 to 65 Yrs. China\n9- NCT043\n39,660 Clinical Research of Human Mesenchymal\nStem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020\nDOC: June 2020 Both 18 to 75 Yrs. China\n10- NCT043\n46,368 Bone Marrow-Derived\nMesenchymal Stem\nCell Treatment for\nSevere Patients With\nCoronavirus Disease\n2019 (COVID19) I and II Not\nRecruiting 20 BM-MSCs DOS: April 2020\nDOC: December\n2020 Both 18 to 75 Yrs. China\n11- NCT043\n52,803 Adipose Mesenchymal\nCells for Abatement of\nSARS CoV-2\nRespiratory\nCompromise in\nCOVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020\nDOC: April 2026 Both 18 to 90 Yrs. –\n12- NCT043\n49,631 A Clinical Trial to\nDetermine the Safety\nand Efficacy of Hope\nBiosciences\nAutologous\nMesenchymal Stem\nCell Therapy (HBadMSCs)\nto Provide\nProtection Against\nCOVID19 II Enrolling by\ninvitation 56 AD-MSCs DOS: May 2020\nDOC: December 2020 Both Child, Adult,\nOlder\nAdult United States\n13- NCT030\n42,143 Repair of Acute\nRespiratory Distress\nSyndrome by Stromal\nCell Administration\n(REALIST) (COVID19)\n(REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019\nDOC: October 2022 Both 16 Yrs. and older United Kingdom\n14- NCT043\n90,152 Safety and Efficacy of Intravenous Wharton’s\nJelly Derived\nMesenchymal Stem\nCells in Acute\nRespiratory Distress\nSyndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020\nDOC: May 2021 Both 18 to 80 Yrs. Colombia\n15- NCT043\n82,547 Treatment of\nCOVID19 Associated\nPneumonia with\nAllogenic Pooled\nOlfactory Mucosaderived\nMesenchymal\nStem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020\nDOC: June 2021 Both 18 to70 Yrs. Belarus\n16- NCT043\n66,323 Clinical Trial to Assess\nthe Safety and\nEfficacy of Intravenous\nAdministration of Allogeneic Adult\nMesenchymal Stem\nCells of Expanded\nAdipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020\nDOC: October 2021 Both 18 to 80 Yrs. –\n17- NCT043\n66,063 Mesenchymal Stem\nCell Therapy for SARS-CoV-2-related\nAcute Respiratory\nDistress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020\nDOC: December 2020 Both 18 to 65 Yrs. Iran\n18- NCT043\n77,334 Mesenchymal Stem\nCells (MSCs) in Inflammation-\nResolution Programs\nof Coronavirus\nDisease 2019\n(COVID19) Induced\nAcute Respiratory\nDistress Syndrome\n(ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020\nDOC: February 2021 Both 18 Yrs. and older Germany\n19- NCT043\n71,393 MSCs in COVID19\nARDS III Recruiting 300 MSCs\nRemestemcel-L DOS: April 30, 2020\nDOC: April 2022 Both 18 Yrs. and older United States\n20- NCT043\n62,189 Efficacy and Safety\nStudy of Allogeneic\nHB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020\nDOC: October 2020 Both Child,\nAdult,\nOlder\nAdult United States\n21- NCT043\n66,271 Clinical Trial of\nAllogeneic\nMesenchymal Cells\nfrom Umbilical Cord\nTissue in Patients with\nCOVID19 II Recruiting 106 UC-MSCs DOS: May 2020\nDOC: May 2021 Both 40 to 80 Yrs. Spain\n22- NCT043\n48,435 A Randomized,\nDouble-Blind,\nPlacebo-Controlled\nClinical Trial to Determine the Safety and Efficacy of Hope\nBiosciences\nAllogeneic\nMesenchymal Stem\nCell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020\nDOC: April 2021 Both Child,\nAdult, Older\nAdult United States\n23- NCT043\n71,601 Safety and Effectiveness of Mesenchymal Stem\nCells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020\nDOC: December 2022 Both 18 to 70 Yrs. China\n24- NCT043\n55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020\nDOC: May 2021 Both 18 Yrs. and older United States\n25- NCT043\n92,778 Clinical Use of Stem\nCells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020\nDOC: September 2020 Both 40 to 60 Yrs. Turkey\n26- NCT043\n97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020\nDOC: June 2021 Both 18 to 80 Yrs. –\n27- NCT043\n90,139 Efficacy and Safety\nEvaluation of Mesenchymal Stem\nCells for the Treatment of Patients\nwith Respiratory\nDistress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020\nDOC: December 2020 Both 18 to 75 Yrs. Spain\n28- NCT042\n69,525 Umbilical Cord (UC)- Derived Mesenchymal\nStem Cells (MSCs)\nTreatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020\nDOC: September 2020 Both 18 to 75 Yrs. China"}

{"project":"LitCovid-PubTator","denotations":[{"id":"165","span":{"begin":1109,"end":1117},"obj":"Species"},{"id":"166","span":{"begin":1132,"end":1154},"obj":"Species"},{"id":"167","span":{"begin":1261,"end":1266},"obj":"Species"},{"id":"168","span":{"begin":1325,"end":1342},"obj":"Species"},{"id":"169","span":{"begin":1816,"end":1824},"obj":"Species"},{"id":"170","span":{"begin":1949,"end":1954},"obj":"Species"},{"id":"171","span":{"begin":2187,"end":2195},"obj":"Species"},{"id":"172","span":{"begin":2397,"end":2402},"obj":"Species"},{"id":"173","span":{"begin":2785,"end":2790},"obj":"Species"},{"id":"161","span":{"begin":2984,"end":2989},"obj":"Gene"},{"id":"162","span":{"begin":367,"end":375},"obj":"Species"},{"id":"163","span":{"begin":535,"end":543},"obj":"Species"},{"id":"164","span":{"begin":871,"end":888},"obj":"Species"},{"id":"174","span":{"begin":3713,"end":3721},"obj":"Species"},{"id":"175","span":{"begin":3901,"end":3911},"obj":"Species"},{"id":"176","span":{"begin":4669,"end":4674},"obj":"Species"},{"id":"177","span":{"begin":4804,"end":4812},"obj":"Species"},{"id":"178","span":{"begin":5208,"end":5213},"obj":"Species"},{"id":"179","span":{"begin":5527,"end":5535},"obj":"Species"},{"id":"180","span":{"begin":5794,"end":5800},"obj":"Species"},{"id":"181","span":{"begin":6354,"end":6376},"obj":"Species"},{"id":"182","span":{"begin":6378,"end":6382},"obj":"Species"},{"id":"183","span":{"begin":381,"end":405},"obj":"Disease"},{"id":"184","span":{"begin":527,"end":534},"obj":"Disease"},{"id":"185","span":{"begin":742,"end":781},"obj":"Disease"},{"id":"186","span":{"begin":897,"end":913},"obj":"Disease"},{"id":"187","span":{"begin":1099,"end":1108},"obj":"Disease"},{"id":"188","span":{"begin":1118,"end":1126},"obj":"Disease"},{"id":"189","span":{"begin":1350,"end":1359},"obj":"Disease"},{"id":"190","span":{"begin":1551,"end":1578},"obj":"Disease"},{"id":"191","span":{"begin":1998,"end":2015},"obj":"Disease"},{"id":"192","span":{"begin":2196,"end":2237},"obj":"Disease"},{"id":"193","span":{"begin":2426,"end":2445},"obj":"Disease"},{"id":"194","span":{"begin":2931,"end":2938},"obj":"Disease"},{"id":"195","span":{"begin":3224,"end":3233},"obj":"Disease"},{"id":"196","span":{"begin":3352,"end":3415},"obj":"Disease"},{"id":"197","span":{"begin":3734,"end":3743},"obj":"Disease"},{"id":"198","span":{"begin":3751,"end":3760},"obj":"Disease"},{"id":"199","span":{"begin":3926,"end":3958},"obj":"Disease"},{"id":"200","span":{"begin":4594,"end":4604},"obj":"Disease"},{"id":"201","span":{"begin":5124,"end":5134},"obj":"Disease"},{"id":"202","span":{"begin":5337,"end":5374},"obj":"Disease"},{"id":"203","span":{"begin":5519,"end":5526},"obj":"Disease"},{"id":"204","span":{"begin":5700,"end":5709},"obj":"Disease"},{"id":"205","span":{"begin":5898,"end":5915},"obj":"Disease"},{"id":"206","span":{"begin":6162,"end":6171},"obj":"Disease"},{"id":"207","span":{"begin":6384,"end":6393},"obj":"Disease"},{"id":"209","span":{"begin":60,"end":67},"obj":"Disease"}],"attributes":[{"id":"A161","pred":"tao:has_database_id","subj":"161","obj":"Gene:6383"},{"id":"A162","pred":"tao:has_database_id","subj":"162","obj":"Tax:9606"},{"id":"A163","pred":"tao:has_database_id","subj":"163","obj":"Tax:9606"},{"id":"A164","pred":"tao:has_database_id","subj":"164","obj":"Tax:2697049"},{"id":"A165","pred":"tao:has_database_id","subj":"165","obj":"Tax:9606"},{"id":"A166","pred":"tao:has_database_id","subj":"166","obj":"Tax:2697049"},{"id":"A167","pred":"tao:has_database_id","subj":"167","obj":"Tax:9606"},{"id":"A168","pred":"tao:has_database_id","subj":"168","obj":"Tax:2697049"},{"id":"A169","pred":"tao:has_database_id","subj":"169","obj":"Tax:9606"},{"id":"A170","pred":"tao:has_database_id","subj":"170","obj":"Tax:9606"},{"id":"A171","pred":"tao:has_database_id","subj":"171","obj":"Tax:9606"},{"id":"A172","pred":"tao:has_database_id","subj":"172","obj":"Tax:2697049"},{"id":"A173","pred":"tao:has_database_id","subj":"173","obj":"Tax:9606"},{"id":"A174","pred":"tao:has_database_id","subj":"174","obj":"Tax:9606"},{"id":"A175","pred":"tao:has_database_id","subj":"175","obj":"Tax:2697049"},{"id":"A176","pred":"tao:has_database_id","subj":"176","obj":"Tax:9606"},{"id":"A177","pred":"tao:has_database_id","subj":"177","obj":"Tax:9606"},{"id":"A178","pred":"tao:has_database_id","subj":"178","obj":"Tax:9606"},{"id":"A179","pred":"tao:has_database_id","subj":"179","obj":"Tax:9606"},{"id":"A180","pred":"tao:has_database_id","subj":"180","obj":"Tax:9103"},{"id":"A181","pred":"tao:has_database_id","subj":"181","obj":"Tax:2697049"},{"id":"A182","pred":"tao:has_database_id","subj":"182","obj":"Tax:2697049"},{"id":"A183","pred":"tao:has_database_id","subj":"183","obj":"MESH:C000657245"},{"id":"A184","pred":"tao:has_database_id","subj":"184","obj":"MESH:C000657245"},{"id":"A185","pred":"tao:has_database_id","subj":"185","obj":"MESH:C000657245"},{"id":"A186","pred":"tao:has_database_id","subj":"186","obj":"MESH:D045169"},{"id":"A187","pred":"tao:has_database_id","subj":"187","obj":"MESH:D011014"},{"id":"A188","pred":"tao:has_database_id","subj":"188","obj":"MESH:D007239"},{"id":"A189","pred":"tao:has_database_id","subj":"189","obj":"MESH:D011014"},{"id":"A190","pred":"tao:has_database_id","subj":"190","obj":"MESH:C000657245"},{"id":"A191","pred":"tao:has_database_id","subj":"191","obj":"MESH:C000657245"},{"id":"A192","pred":"tao:has_database_id","subj":"192","obj":"MESH:C000657245"},{"id":"A193","pred":"tao:has_database_id","subj":"193","obj":"MESH:C000657245"},{"id":"A194","pred":"tao:has_database_id","subj":"194","obj":"MESH:C000657245"},{"id":"A195","pred":"tao:has_database_id","subj":"195","obj":"MESH:C000657245"},{"id":"A197","pred":"tao:has_database_id","subj":"197","obj":"MESH:D011014"},{"id":"A198","pred":"tao:has_database_id","subj":"198","obj":"MESH:C000657245"},{"id":"A199","pred":"tao:has_database_id","subj":"199","obj":"MESH:D009901"},{"id":"A200","pred":"tao:has_database_id","subj":"200","obj":"MESH:C000657245"},{"id":"A201","pred":"tao:has_database_id","subj":"201","obj":"MESH:C000657245"},{"id":"A202","pred":"tao:has_database_id","subj":"202","obj":"MESH:C000657245"},{"id":"A203","pred":"tao:has_database_id","subj":"203","obj":"MESH:C000657245"},{"id":"A204","pred":"tao:has_database_id","subj":"204","obj":"MESH:C000657245"},{"id":"A205","pred":"tao:has_database_id","subj":"205","obj":"MESH:C000657245"},{"id":"A206","pred":"tao:has_database_id","subj":"206","obj":"MESH:C000657245"},{"id":"A207","pred":"tao:has_database_id","subj":"207","obj":"MESH:D011014"},{"id":"A209","pred":"tao:has_database_id","subj":"209","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020\nS.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country\n1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020\nDOC: June 2020 Both 18 Yrs. and older Brazil\n2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020\nDOC:September 2020 Both 18 Yrs. and older Jordan\n3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020\nDOC: July 2020 Both 18 to75 Yrs. China\n4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020\nDOC: July 2021 Both 18 to75 Yrs. –\n5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020\nDOC: December 2021 Both 18 to70 Yrs. China\n6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020\nDOC: February 2022 Both 18 to 65 Yrs. China\n7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs\n(MSCs-Exo) DOS: February 2020\nDOC: July 2020 Both 18 to75 Yrs. –\n8- NCT043\n36,254 Safety and Efficacy\nStudy of Allogeneic\nHuman Dental Pulp\nMesenchymal Stem\nCells to Treat Severe\nCOVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020\nDOC: March\n2021 Both 18 to 65 Yrs. China\n9- NCT043\n39,660 Clinical Research of Human Mesenchymal\nStem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020\nDOC: June 2020 Both 18 to 75 Yrs. China\n10- NCT043\n46,368 Bone Marrow-Derived\nMesenchymal Stem\nCell Treatment for\nSevere Patients With\nCoronavirus Disease\n2019 (COVID19) I and II Not\nRecruiting 20 BM-MSCs DOS: April 2020\nDOC: December\n2020 Both 18 to 75 Yrs. China\n11- NCT043\n52,803 Adipose Mesenchymal\nCells for Abatement of\nSARS CoV-2\nRespiratory\nCompromise in\nCOVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020\nDOC: April 2026 Both 18 to 90 Yrs. –\n12- NCT043\n49,631 A Clinical Trial to\nDetermine the Safety\nand Efficacy of Hope\nBiosciences\nAutologous\nMesenchymal Stem\nCell Therapy (HBadMSCs)\nto Provide\nProtection Against\nCOVID19 II Enrolling by\ninvitation 56 AD-MSCs DOS: May 2020\nDOC: December 2020 Both Child, Adult,\nOlder\nAdult United States\n13- NCT030\n42,143 Repair of Acute\nRespiratory Distress\nSyndrome by Stromal\nCell Administration\n(REALIST) (COVID19)\n(REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019\nDOC: October 2022 Both 16 Yrs. and older United Kingdom\n14- NCT043\n90,152 Safety and Efficacy of Intravenous Wharton’s\nJelly Derived\nMesenchymal Stem\nCells in Acute\nRespiratory Distress\nSyndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020\nDOC: May 2021 Both 18 to 80 Yrs. Colombia\n15- NCT043\n82,547 Treatment of\nCOVID19 Associated\nPneumonia with\nAllogenic Pooled\nOlfactory Mucosaderived\nMesenchymal\nStem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020\nDOC: June 2021 Both 18 to70 Yrs. Belarus\n16- NCT043\n66,323 Clinical Trial to Assess\nthe Safety and\nEfficacy of Intravenous\nAdministration of Allogeneic Adult\nMesenchymal Stem\nCells of Expanded\nAdipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020\nDOC: October 2021 Both 18 to 80 Yrs. –\n17- NCT043\n66,063 Mesenchymal Stem\nCell Therapy for SARS-CoV-2-related\nAcute Respiratory\nDistress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020\nDOC: December 2020 Both 18 to 65 Yrs. Iran\n18- NCT043\n77,334 Mesenchymal Stem\nCells (MSCs) in Inflammation-\nResolution Programs\nof Coronavirus\nDisease 2019\n(COVID19) Induced\nAcute Respiratory\nDistress Syndrome\n(ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020\nDOC: February 2021 Both 18 Yrs. and older Germany\n19- NCT043\n71,393 MSCs in COVID19\nARDS III Recruiting 300 MSCs\nRemestemcel-L DOS: April 30, 2020\nDOC: April 2022 Both 18 Yrs. and older United States\n20- NCT043\n62,189 Efficacy and Safety\nStudy of Allogeneic\nHB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020\nDOC: October 2020 Both Child,\nAdult,\nOlder\nAdult United States\n21- NCT043\n66,271 Clinical Trial of\nAllogeneic\nMesenchymal Cells\nfrom Umbilical Cord\nTissue in Patients with\nCOVID19 II Recruiting 106 UC-MSCs DOS: May 2020\nDOC: May 2021 Both 40 to 80 Yrs. Spain\n22- NCT043\n48,435 A Randomized,\nDouble-Blind,\nPlacebo-Controlled\nClinical Trial to Determine the Safety and Efficacy of Hope\nBiosciences\nAllogeneic\nMesenchymal Stem\nCell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020\nDOC: April 2021 Both Child,\nAdult, Older\nAdult United States\n23- NCT043\n71,601 Safety and Effectiveness of Mesenchymal Stem\nCells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020\nDOC: December 2022 Both 18 to 70 Yrs. China\n24- NCT043\n55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020\nDOC: May 2021 Both 18 Yrs. and older United States\n25- NCT043\n92,778 Clinical Use of Stem\nCells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020\nDOC: September 2020 Both 40 to 60 Yrs. Turkey\n26- NCT043\n97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020\nDOC: June 2021 Both 18 to 80 Yrs. –\n27- NCT043\n90,139 Efficacy and Safety\nEvaluation of Mesenchymal Stem\nCells for the Treatment of Patients\nwith Respiratory\nDistress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020\nDOC: December 2020 Both 18 to 75 Yrs. Spain\n28- NCT042\n69,525 Umbilical Cord (UC)- Derived Mesenchymal\nStem Cells (MSCs)\nTreatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020\nDOC: September 2020 Both 18 to 75 Yrs. China"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T11","span":{"begin":4136,"end":4151},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020\nS.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country\n1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020\nDOC: June 2020 Both 18 Yrs. and older Brazil\n2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020\nDOC:September 2020 Both 18 Yrs. and older Jordan\n3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020\nDOC: July 2020 Both 18 to75 Yrs. China\n4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020\nDOC: July 2021 Both 18 to75 Yrs. –\n5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020\nDOC: December 2021 Both 18 to70 Yrs. China\n6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020\nDOC: February 2022 Both 18 to 65 Yrs. China\n7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs\n(MSCs-Exo) DOS: February 2020\nDOC: July 2020 Both 18 to75 Yrs. –\n8- NCT043\n36,254 Safety and Efficacy\nStudy of Allogeneic\nHuman Dental Pulp\nMesenchymal Stem\nCells to Treat Severe\nCOVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020\nDOC: March\n2021 Both 18 to 65 Yrs. China\n9- NCT043\n39,660 Clinical Research of Human Mesenchymal\nStem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020\nDOC: June 2020 Both 18 to 75 Yrs. China\n10- NCT043\n46,368 Bone Marrow-Derived\nMesenchymal Stem\nCell Treatment for\nSevere Patients With\nCoronavirus Disease\n2019 (COVID19) I and II Not\nRecruiting 20 BM-MSCs DOS: April 2020\nDOC: December\n2020 Both 18 to 75 Yrs. China\n11- NCT043\n52,803 Adipose Mesenchymal\nCells for Abatement of\nSARS CoV-2\nRespiratory\nCompromise in\nCOVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020\nDOC: April 2026 Both 18 to 90 Yrs. –\n12- NCT043\n49,631 A Clinical Trial to\nDetermine the Safety\nand Efficacy of Hope\nBiosciences\nAutologous\nMesenchymal Stem\nCell Therapy (HBadMSCs)\nto Provide\nProtection Against\nCOVID19 II Enrolling by\ninvitation 56 AD-MSCs DOS: May 2020\nDOC: December 2020 Both Child, Adult,\nOlder\nAdult United States\n13- NCT030\n42,143 Repair of Acute\nRespiratory Distress\nSyndrome by Stromal\nCell Administration\n(REALIST) (COVID19)\n(REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019\nDOC: October 2022 Both 16 Yrs. and older United Kingdom\n14- NCT043\n90,152 Safety and Efficacy of Intravenous Wharton’s\nJelly Derived\nMesenchymal Stem\nCells in Acute\nRespiratory Distress\nSyndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020\nDOC: May 2021 Both 18 to 80 Yrs. Colombia\n15- NCT043\n82,547 Treatment of\nCOVID19 Associated\nPneumonia with\nAllogenic Pooled\nOlfactory Mucosaderived\nMesenchymal\nStem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020\nDOC: June 2021 Both 18 to70 Yrs. Belarus\n16- NCT043\n66,323 Clinical Trial to Assess\nthe Safety and\nEfficacy of Intravenous\nAdministration of Allogeneic Adult\nMesenchymal Stem\nCells of Expanded\nAdipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020\nDOC: October 2021 Both 18 to 80 Yrs. –\n17- NCT043\n66,063 Mesenchymal Stem\nCell Therapy for SARS-CoV-2-related\nAcute Respiratory\nDistress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020\nDOC: December 2020 Both 18 to 65 Yrs. Iran\n18- NCT043\n77,334 Mesenchymal Stem\nCells (MSCs) in Inflammation-\nResolution Programs\nof Coronavirus\nDisease 2019\n(COVID19) Induced\nAcute Respiratory\nDistress Syndrome\n(ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020\nDOC: February 2021 Both 18 Yrs. and older Germany\n19- NCT043\n71,393 MSCs in COVID19\nARDS III Recruiting 300 MSCs\nRemestemcel-L DOS: April 30, 2020\nDOC: April 2022 Both 18 Yrs. and older United States\n20- NCT043\n62,189 Efficacy and Safety\nStudy of Allogeneic\nHB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020\nDOC: October 2020 Both Child,\nAdult,\nOlder\nAdult United States\n21- NCT043\n66,271 Clinical Trial of\nAllogeneic\nMesenchymal Cells\nfrom Umbilical Cord\nTissue in Patients with\nCOVID19 II Recruiting 106 UC-MSCs DOS: May 2020\nDOC: May 2021 Both 40 to 80 Yrs. Spain\n22- NCT043\n48,435 A Randomized,\nDouble-Blind,\nPlacebo-Controlled\nClinical Trial to Determine the Safety and Efficacy of Hope\nBiosciences\nAllogeneic\nMesenchymal Stem\nCell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020\nDOC: April 2021 Both Child,\nAdult, Older\nAdult United States\n23- NCT043\n71,601 Safety and Effectiveness of Mesenchymal Stem\nCells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020\nDOC: December 2022 Both 18 to 70 Yrs. China\n24- NCT043\n55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020\nDOC: May 2021 Both 18 Yrs. and older United States\n25- NCT043\n92,778 Clinical Use of Stem\nCells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020\nDOC: September 2020 Both 40 to 60 Yrs. Turkey\n26- NCT043\n97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020\nDOC: June 2021 Both 18 to 80 Yrs. –\n27- NCT043\n90,139 Efficacy and Safety\nEvaluation of Mesenchymal Stem\nCells for the Treatment of Patients\nwith Respiratory\nDistress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020\nDOC: December 2020 Both 18 to 75 Yrs. Spain\n28- NCT042\n69,525 Umbilical Cord (UC)- Derived Mesenchymal\nStem Cells (MSCs)\nTreatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020\nDOC: September 2020 Both 18 to 75 Yrs. China"}

{"project":"LitCovid-sentences","denotations":[{"id":"T51","span":{"begin":0,"end":137},"obj":"Sentence"},{"id":"T52","span":{"begin":138,"end":143},"obj":"Sentence"},{"id":"T53","span":{"begin":144,"end":309},"obj":"Sentence"},{"id":"T54","span":{"begin":310,"end":442},"obj":"Sentence"},{"id":"T55","span":{"begin":443,"end":453},"obj":"Sentence"},{"id":"T56","span":{"begin":454,"end":458},"obj":"Sentence"},{"id":"T57","span":{"begin":459,"end":498},"obj":"Sentence"},{"id":"T58","span":{"begin":499,"end":617},"obj":"Sentence"},{"id":"T59","span":{"begin":618,"end":628},"obj":"Sentence"},{"id":"T60","span":{"begin":629,"end":677},"obj":"Sentence"},{"id":"T61","span":{"begin":678,"end":805},"obj":"Sentence"},{"id":"T62","span":{"begin":806,"end":816},"obj":"Sentence"},{"id":"T63","span":{"begin":817,"end":821},"obj":"Sentence"},{"id":"T64","span":{"begin":822,"end":849},"obj":"Sentence"},{"id":"T65","span":{"begin":850,"end":855},"obj":"Sentence"},{"id":"T66","span":{"begin":856,"end":1001},"obj":"Sentence"},{"id":"T67","span":{"begin":1002,"end":1012},"obj":"Sentence"},{"id":"T68","span":{"begin":1013,"end":1017},"obj":"Sentence"},{"id":"T69","span":{"begin":1018,"end":1047},"obj":"Sentence"},{"id":"T70","span":{"begin":1048,"end":1180},"obj":"Sentence"},{"id":"T71","span":{"begin":1181,"end":1193},"obj":"Sentence"},{"id":"T72","span":{"begin":1194,"end":1198},"obj":"Sentence"},{"id":"T73","span":{"begin":1199,"end":1230},"obj":"Sentence"},{"id":"T74","span":{"begin":1231,"end":1236},"obj":"Sentence"},{"id":"T75","span":{"begin":1237,"end":1392},"obj":"Sentence"},{"id":"T76","span":{"begin":1393,"end":1403},"obj":"Sentence"},{"id":"T77","span":{"begin":1404,"end":1408},"obj":"Sentence"},{"id":"T78","span":{"begin":1409,"end":1441},"obj":"Sentence"},{"id":"T79","span":{"begin":1442,"end":1447},"obj":"Sentence"},{"id":"T80","span":{"begin":1448,"end":1628},"obj":"Sentence"},{"id":"T81","span":{"begin":1629,"end":1644},"obj":"Sentence"},{"id":"T82","span":{"begin":1645,"end":1658},"obj":"Sentence"},{"id":"T83","span":{"begin":1659,"end":1663},"obj":"Sentence"},{"id":"T84","span":{"begin":1664,"end":1693},"obj":"Sentence"},{"id":"T85","span":{"begin":1694,"end":1703},"obj":"Sentence"},{"id":"T86","span":{"begin":1704,"end":1730},"obj":"Sentence"},{"id":"T87","span":{"begin":1731,"end":1750},"obj":"Sentence"},{"id":"T88","span":{"begin":1751,"end":1768},"obj":"Sentence"},{"id":"T89","span":{"begin":1769,"end":1785},"obj":"Sentence"},{"id":"T90","span":{"begin":1786,"end":1807},"obj":"Sentence"},{"id":"T91","span":{"begin":1808,"end":1858},"obj":"Sentence"},{"id":"T92","span":{"begin":1859,"end":1869},"obj":"Sentence"},{"id":"T93","span":{"begin":1870,"end":1874},"obj":"Sentence"},{"id":"T94","span":{"begin":1875,"end":1880},"obj":"Sentence"},{"id":"T95","span":{"begin":1881,"end":1904},"obj":"Sentence"},{"id":"T96","span":{"begin":1905,"end":1910},"obj":"Sentence"},{"id":"T97","span":{"begin":1911,"end":1920},"obj":"Sentence"},{"id":"T98","span":{"begin":1921,"end":1966},"obj":"Sentence"},{"id":"T99","span":{"begin":1967,"end":2051},"obj":"Sentence"},{"id":"T100","span":{"begin":2052,"end":2065},"obj":"Sentence"},{"id":"T101","span":{"begin":2066,"end":2070},"obj":"Sentence"},{"id":"T102","span":{"begin":2071,"end":2099},"obj":"Sentence"},{"id":"T103","span":{"begin":2100,"end":2105},"obj":"Sentence"},{"id":"T104","span":{"begin":2106,"end":2116},"obj":"Sentence"},{"id":"T105","span":{"begin":2117,"end":2143},"obj":"Sentence"},{"id":"T106","span":{"begin":2144,"end":2160},"obj":"Sentence"},{"id":"T107","span":{"begin":2161,"end":2179},"obj":"Sentence"},{"id":"T108","span":{"begin":2180,"end":2200},"obj":"Sentence"},{"id":"T109","span":{"begin":2201,"end":2220},"obj":"Sentence"},{"id":"T110","span":{"begin":2221,"end":2248},"obj":"Sentence"},{"id":"T111","span":{"begin":2249,"end":2275},"obj":"Sentence"},{"id":"T112","span":{"begin":2276,"end":2286},"obj":"Sentence"},{"id":"T113","span":{"begin":2287,"end":2291},"obj":"Sentence"},{"id":"T114","span":{"begin":2292,"end":2300},"obj":"Sentence"},{"id":"T115","span":{"begin":2301,"end":2324},"obj":"Sentence"},{"id":"T116","span":{"begin":2325,"end":2330},"obj":"Sentence"},{"id":"T117","span":{"begin":2331,"end":2341},"obj":"Sentence"},{"id":"T118","span":{"begin":2342,"end":2368},"obj":"Sentence"},{"id":"T119","span":{"begin":2369,"end":2391},"obj":"Sentence"},{"id":"T120","span":{"begin":2392,"end":2402},"obj":"Sentence"},{"id":"T121","span":{"begin":2403,"end":2414},"obj":"Sentence"},{"id":"T122","span":{"begin":2415,"end":2428},"obj":"Sentence"},{"id":"T123","span":{"begin":2429,"end":2478},"obj":"Sentence"},{"id":"T124","span":{"begin":2479,"end":2489},"obj":"Sentence"},{"id":"T125","span":{"begin":2490,"end":2494},"obj":"Sentence"},{"id":"T126","span":{"begin":2495,"end":2526},"obj":"Sentence"},{"id":"T127","span":{"begin":2527,"end":2537},"obj":"Sentence"},{"id":"T128","span":{"begin":2538,"end":2564},"obj":"Sentence"},{"id":"T129","span":{"begin":2565,"end":2585},"obj":"Sentence"},{"id":"T130","span":{"begin":2586,"end":2606},"obj":"Sentence"},{"id":"T131","span":{"begin":2607,"end":2618},"obj":"Sentence"},{"id":"T132","span":{"begin":2619,"end":2629},"obj":"Sentence"},{"id":"T133","span":{"begin":2630,"end":2646},"obj":"Sentence"},{"id":"T134","span":{"begin":2647,"end":2670},"obj":"Sentence"},{"id":"T135","span":{"begin":2671,"end":2681},"obj":"Sentence"},{"id":"T136","span":{"begin":2682,"end":2700},"obj":"Sentence"},{"id":"T137","span":{"begin":2701,"end":2724},"obj":"Sentence"},{"id":"T138","span":{"begin":2725,"end":2751},"obj":"Sentence"},{"id":"T139","span":{"begin":2752,"end":2760},"obj":"Sentence"},{"id":"T140","span":{"begin":2761,"end":2765},"obj":"Sentence"},{"id":"T141","span":{"begin":2766,"end":2798},"obj":"Sentence"},{"id":"T142","span":{"begin":2799,"end":2804},"obj":"Sentence"},{"id":"T143","span":{"begin":2805,"end":2824},"obj":"Sentence"},{"id":"T144","span":{"begin":2825,"end":2835},"obj":"Sentence"},{"id":"T145","span":{"begin":2836,"end":2858},"obj":"Sentence"},{"id":"T146","span":{"begin":2859,"end":2879},"obj":"Sentence"},{"id":"T147","span":{"begin":2880,"end":2899},"obj":"Sentence"},{"id":"T148","span":{"begin":2900,"end":2919},"obj":"Sentence"},{"id":"T149","span":{"begin":2920,"end":2939},"obj":"Sentence"},{"id":"T150","span":{"begin":2940,"end":3008},"obj":"Sentence"},{"id":"T151","span":{"begin":3009,"end":3021},"obj":"Sentence"},{"id":"T152","span":{"begin":3022,"end":3026},"obj":"Sentence"},{"id":"T153","span":{"begin":3027,"end":3077},"obj":"Sentence"},{"id":"T154","span":{"begin":3078,"end":3088},"obj":"Sentence"},{"id":"T155","span":{"begin":3089,"end":3140},"obj":"Sentence"},{"id":"T156","span":{"begin":3141,"end":3154},"obj":"Sentence"},{"id":"T157","span":{"begin":3155,"end":3171},"obj":"Sentence"},{"id":"T158","span":{"begin":3172,"end":3186},"obj":"Sentence"},{"id":"T159","span":{"begin":3187,"end":3207},"obj":"Sentence"},{"id":"T160","span":{"begin":3208,"end":3271},"obj":"Sentence"},{"id":"T161","span":{"begin":3272,"end":3281},"obj":"Sentence"},{"id":"T162","span":{"begin":3282,"end":3286},"obj":"Sentence"},{"id":"T163","span":{"begin":3287,"end":3314},"obj":"Sentence"},{"id":"T164","span":{"begin":3315,"end":3323},"obj":"Sentence"},{"id":"T165","span":{"begin":3324,"end":3334},"obj":"Sentence"},{"id":"T166","span":{"begin":3335,"end":3354},"obj":"Sentence"},{"id":"T167","span":{"begin":3355,"end":3373},"obj":"Sentence"},{"id":"T168","span":{"begin":3374,"end":3388},"obj":"Sentence"},{"id":"T169","span":{"begin":3389,"end":3405},"obj":"Sentence"},{"id":"T170","span":{"begin":3406,"end":3429},"obj":"Sentence"},{"id":"T171","span":{"begin":3430,"end":3441},"obj":"Sentence"},{"id":"T172","span":{"begin":3442,"end":3492},"obj":"Sentence"},{"id":"T173","span":{"begin":3493,"end":3501},"obj":"Sentence"},{"id":"T174","span":{"begin":3502,"end":3506},"obj":"Sentence"},{"id":"T175","span":{"begin":3507,"end":3534},"obj":"Sentence"},{"id":"T176","span":{"begin":3535,"end":3542},"obj":"Sentence"},{"id":"T177","span":{"begin":3543,"end":3553},"obj":"Sentence"},{"id":"T178","span":{"begin":3554,"end":3585},"obj":"Sentence"},{"id":"T179","span":{"begin":3586,"end":3600},"obj":"Sentence"},{"id":"T180","span":{"begin":3601,"end":3624},"obj":"Sentence"},{"id":"T181","span":{"begin":3625,"end":3659},"obj":"Sentence"},{"id":"T182","span":{"begin":3660,"end":3676},"obj":"Sentence"},{"id":"T183","span":{"begin":3677,"end":3694},"obj":"Sentence"},{"id":"T184","span":{"begin":3695,"end":3798},"obj":"Sentence"},{"id":"T185","span":{"begin":3799,"end":3809},"obj":"Sentence"},{"id":"T186","span":{"begin":3810,"end":3814},"obj":"Sentence"},{"id":"T187","span":{"begin":3815,"end":3848},"obj":"Sentence"},{"id":"T188","span":{"begin":3849,"end":3859},"obj":"Sentence"},{"id":"T189","span":{"begin":3860,"end":3883},"obj":"Sentence"},{"id":"T190","span":{"begin":3884,"end":3919},"obj":"Sentence"},{"id":"T191","span":{"begin":3920,"end":3937},"obj":"Sentence"},{"id":"T192","span":{"begin":3938,"end":4033},"obj":"Sentence"},{"id":"T193","span":{"begin":4034,"end":4044},"obj":"Sentence"},{"id":"T194","span":{"begin":4045,"end":4049},"obj":"Sentence"},{"id":"T195","span":{"begin":4050,"end":4082},"obj":"Sentence"},{"id":"T196","span":{"begin":4083,"end":4087},"obj":"Sentence"},{"id":"T197","span":{"begin":4088,"end":4098},"obj":"Sentence"},{"id":"T198","span":{"begin":4099,"end":4122},"obj":"Sentence"},{"id":"T199","span":{"begin":4123,"end":4152},"obj":"Sentence"},{"id":"T200","span":{"begin":4153,"end":4172},"obj":"Sentence"},{"id":"T201","span":{"begin":4173,"end":4187},"obj":"Sentence"},{"id":"T202","span":{"begin":4188,"end":4200},"obj":"Sentence"},{"id":"T203","span":{"begin":4201,"end":4218},"obj":"Sentence"},{"id":"T204","span":{"begin":4219,"end":4236},"obj":"Sentence"},{"id":"T205","span":{"begin":4237,"end":4254},"obj":"Sentence"},{"id":"T206","span":{"begin":4255,"end":4295},"obj":"Sentence"},{"id":"T207","span":{"begin":4296,"end":4304},"obj":"Sentence"},{"id":"T208","span":{"begin":4305,"end":4309},"obj":"Sentence"},{"id":"T209","span":{"begin":4310,"end":4354},"obj":"Sentence"},{"id":"T210","span":{"begin":4355,"end":4365},"obj":"Sentence"},{"id":"T211","span":{"begin":4366,"end":4388},"obj":"Sentence"},{"id":"T212","span":{"begin":4389,"end":4417},"obj":"Sentence"},{"id":"T213","span":{"begin":4418,"end":4436},"obj":"Sentence"},{"id":"T214","span":{"begin":4437,"end":4451},"obj":"Sentence"},{"id":"T215","span":{"begin":4452,"end":4456},"obj":"Sentence"},{"id":"T216","span":{"begin":4457,"end":4504},"obj":"Sentence"},{"id":"T217","span":{"begin":4505,"end":4515},"obj":"Sentence"},{"id":"T218","span":{"begin":4516,"end":4542},"obj":"Sentence"},{"id":"T219","span":{"begin":4543,"end":4562},"obj":"Sentence"},{"id":"T220","span":{"begin":4563,"end":4636},"obj":"Sentence"},{"id":"T221","span":{"begin":4637,"end":4645},"obj":"Sentence"},{"id":"T222","span":{"begin":4646,"end":4650},"obj":"Sentence"},{"id":"T223","span":{"begin":4651,"end":4675},"obj":"Sentence"},{"id":"T224","span":{"begin":4676,"end":4682},"obj":"Sentence"},{"id":"T225","span":{"begin":4683,"end":4688},"obj":"Sentence"},{"id":"T226","span":{"begin":4689,"end":4708},"obj":"Sentence"},{"id":"T227","span":{"begin":4709,"end":4719},"obj":"Sentence"},{"id":"T228","span":{"begin":4720,"end":4744},"obj":"Sentence"},{"id":"T229","span":{"begin":4745,"end":4755},"obj":"Sentence"},{"id":"T230","span":{"begin":4756,"end":4773},"obj":"Sentence"},{"id":"T231","span":{"begin":4774,"end":4793},"obj":"Sentence"},{"id":"T232","span":{"begin":4794,"end":4817},"obj":"Sentence"},{"id":"T233","span":{"begin":4818,"end":4856},"obj":"Sentence"},{"id":"T234","span":{"begin":4857,"end":4865},"obj":"Sentence"},{"id":"T235","span":{"begin":4866,"end":4870},"obj":"Sentence"},{"id":"T236","span":{"begin":4871,"end":4898},"obj":"Sentence"},{"id":"T237","span":{"begin":4899,"end":4904},"obj":"Sentence"},{"id":"T238","span":{"begin":4905,"end":4915},"obj":"Sentence"},{"id":"T239","span":{"begin":4916,"end":4936},"obj":"Sentence"},{"id":"T240","span":{"begin":4937,"end":4950},"obj":"Sentence"},{"id":"T241","span":{"begin":4951,"end":4969},"obj":"Sentence"},{"id":"T242","span":{"begin":4970,"end":5029},"obj":"Sentence"},{"id":"T243","span":{"begin":5030,"end":5041},"obj":"Sentence"},{"id":"T244","span":{"begin":5042,"end":5052},"obj":"Sentence"},{"id":"T245","span":{"begin":5053,"end":5069},"obj":"Sentence"},{"id":"T246","span":{"begin":5070,"end":5175},"obj":"Sentence"},{"id":"T247","span":{"begin":5176,"end":5186},"obj":"Sentence"},{"id":"T248","span":{"begin":5187,"end":5191},"obj":"Sentence"},{"id":"T249","span":{"begin":5192,"end":5214},"obj":"Sentence"},{"id":"T250","span":{"begin":5215,"end":5227},"obj":"Sentence"},{"id":"T251","span":{"begin":5228,"end":5247},"obj":"Sentence"},{"id":"T252","span":{"begin":5248,"end":5258},"obj":"Sentence"},{"id":"T253","span":{"begin":5259,"end":5310},"obj":"Sentence"},{"id":"T254","span":{"begin":5311,"end":5426},"obj":"Sentence"},{"id":"T255","span":{"begin":5427,"end":5437},"obj":"Sentence"},{"id":"T256","span":{"begin":5438,"end":5442},"obj":"Sentence"},{"id":"T257","span":{"begin":5443,"end":5475},"obj":"Sentence"},{"id":"T258","span":{"begin":5476,"end":5481},"obj":"Sentence"},{"id":"T259","span":{"begin":5482,"end":5492},"obj":"Sentence"},{"id":"T260","span":{"begin":5493,"end":5571},"obj":"Sentence"},{"id":"T261","span":{"begin":5572,"end":5582},"obj":"Sentence"},{"id":"T262","span":{"begin":5583,"end":5587},"obj":"Sentence"},{"id":"T263","span":{"begin":5588,"end":5633},"obj":"Sentence"},{"id":"T264","span":{"begin":5634,"end":5644},"obj":"Sentence"},{"id":"T265","span":{"begin":5645,"end":5672},"obj":"Sentence"},{"id":"T266","span":{"begin":5673,"end":5743},"obj":"Sentence"},{"id":"T267","span":{"begin":5744,"end":5754},"obj":"Sentence"},{"id":"T268","span":{"begin":5755,"end":5759},"obj":"Sentence"},{"id":"T269","span":{"begin":5760,"end":5793},"obj":"Sentence"},{"id":"T270","span":{"begin":5794,"end":5800},"obj":"Sentence"},{"id":"T271","span":{"begin":5801,"end":5811},"obj":"Sentence"},{"id":"T272","span":{"begin":5812,"end":5981},"obj":"Sentence"},{"id":"T273","span":{"begin":5982,"end":5991},"obj":"Sentence"},{"id":"T274","span":{"begin":5992,"end":5996},"obj":"Sentence"},{"id":"T275","span":{"begin":5997,"end":6027},"obj":"Sentence"},{"id":"T276","span":{"begin":6028,"end":6038},"obj":"Sentence"},{"id":"T277","span":{"begin":6039,"end":6065},"obj":"Sentence"},{"id":"T278","span":{"begin":6066,"end":6096},"obj":"Sentence"},{"id":"T279","span":{"begin":6097,"end":6132},"obj":"Sentence"},{"id":"T280","span":{"begin":6133,"end":6149},"obj":"Sentence"},{"id":"T281","span":{"begin":6150,"end":6205},"obj":"Sentence"},{"id":"T282","span":{"begin":6206,"end":6214},"obj":"Sentence"},{"id":"T283","span":{"begin":6215,"end":6219},"obj":"Sentence"},{"id":"T284","span":{"begin":6220,"end":6252},"obj":"Sentence"},{"id":"T285","span":{"begin":6253,"end":6258},"obj":"Sentence"},{"id":"T286","span":{"begin":6259,"end":6269},"obj":"Sentence"},{"id":"T287","span":{"begin":6270,"end":6317},"obj":"Sentence"},{"id":"T288","span":{"begin":6318,"end":6335},"obj":"Sentence"},{"id":"T289","span":{"begin":6336,"end":6423},"obj":"Sentence"},{"id":"T290","span":{"begin":6424,"end":6437},"obj":"Sentence"},{"id":"T291","span":{"begin":6438,"end":6442},"obj":"Sentence"},{"id":"T292","span":{"begin":6443,"end":6476},"obj":"Sentence"},{"id":"T293","span":{"begin":6477,"end":6482},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020\nS.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country\n1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020\nDOC: June 2020 Both 18 Yrs. and older Brazil\n2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020\nDOC:September 2020 Both 18 Yrs. and older Jordan\n3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020\nDOC: July 2020 Both 18 to75 Yrs. China\n4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020\nDOC: July 2021 Both 18 to75 Yrs. –\n5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020\nDOC: December 2021 Both 18 to70 Yrs. China\n6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020\nDOC: February 2022 Both 18 to 65 Yrs. China\n7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs\n(MSCs-Exo) DOS: February 2020\nDOC: July 2020 Both 18 to75 Yrs. –\n8- NCT043\n36,254 Safety and Efficacy\nStudy of Allogeneic\nHuman Dental Pulp\nMesenchymal Stem\nCells to Treat Severe\nCOVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020\nDOC: March\n2021 Both 18 to 65 Yrs. China\n9- NCT043\n39,660 Clinical Research of Human Mesenchymal\nStem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020\nDOC: June 2020 Both 18 to 75 Yrs. China\n10- NCT043\n46,368 Bone Marrow-Derived\nMesenchymal Stem\nCell Treatment for\nSevere Patients With\nCoronavirus Disease\n2019 (COVID19) I and II Not\nRecruiting 20 BM-MSCs DOS: April 2020\nDOC: December\n2020 Both 18 to 75 Yrs. China\n11- NCT043\n52,803 Adipose Mesenchymal\nCells for Abatement of\nSARS CoV-2\nRespiratory\nCompromise in\nCOVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020\nDOC: April 2026 Both 18 to 90 Yrs. –\n12- NCT043\n49,631 A Clinical Trial to\nDetermine the Safety\nand Efficacy of Hope\nBiosciences\nAutologous\nMesenchymal Stem\nCell Therapy (HBadMSCs)\nto Provide\nProtection Against\nCOVID19 II Enrolling by\ninvitation 56 AD-MSCs DOS: May 2020\nDOC: December 2020 Both Child, Adult,\nOlder\nAdult United States\n13- NCT030\n42,143 Repair of Acute\nRespiratory Distress\nSyndrome by Stromal\nCell Administration\n(REALIST) (COVID19)\n(REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019\nDOC: October 2022 Both 16 Yrs. and older United Kingdom\n14- NCT043\n90,152 Safety and Efficacy of Intravenous Wharton’s\nJelly Derived\nMesenchymal Stem\nCells in Acute\nRespiratory Distress\nSyndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020\nDOC: May 2021 Both 18 to 80 Yrs. Colombia\n15- NCT043\n82,547 Treatment of\nCOVID19 Associated\nPneumonia with\nAllogenic Pooled\nOlfactory Mucosaderived\nMesenchymal\nStem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020\nDOC: June 2021 Both 18 to70 Yrs. Belarus\n16- NCT043\n66,323 Clinical Trial to Assess\nthe Safety and\nEfficacy of Intravenous\nAdministration of Allogeneic Adult\nMesenchymal Stem\nCells of Expanded\nAdipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020\nDOC: October 2021 Both 18 to 80 Yrs. –\n17- NCT043\n66,063 Mesenchymal Stem\nCell Therapy for SARS-CoV-2-related\nAcute Respiratory\nDistress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020\nDOC: December 2020 Both 18 to 65 Yrs. Iran\n18- NCT043\n77,334 Mesenchymal Stem\nCells (MSCs) in Inflammation-\nResolution Programs\nof Coronavirus\nDisease 2019\n(COVID19) Induced\nAcute Respiratory\nDistress Syndrome\n(ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020\nDOC: February 2021 Both 18 Yrs. and older Germany\n19- NCT043\n71,393 MSCs in COVID19\nARDS III Recruiting 300 MSCs\nRemestemcel-L DOS: April 30, 2020\nDOC: April 2022 Both 18 Yrs. and older United States\n20- NCT043\n62,189 Efficacy and Safety\nStudy of Allogeneic\nHB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020\nDOC: October 2020 Both Child,\nAdult,\nOlder\nAdult United States\n21- NCT043\n66,271 Clinical Trial of\nAllogeneic\nMesenchymal Cells\nfrom Umbilical Cord\nTissue in Patients with\nCOVID19 II Recruiting 106 UC-MSCs DOS: May 2020\nDOC: May 2021 Both 40 to 80 Yrs. Spain\n22- NCT043\n48,435 A Randomized,\nDouble-Blind,\nPlacebo-Controlled\nClinical Trial to Determine the Safety and Efficacy of Hope\nBiosciences\nAllogeneic\nMesenchymal Stem\nCell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020\nDOC: April 2021 Both Child,\nAdult, Older\nAdult United States\n23- NCT043\n71,601 Safety and Effectiveness of Mesenchymal Stem\nCells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020\nDOC: December 2022 Both 18 to 70 Yrs. China\n24- NCT043\n55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020\nDOC: May 2021 Both 18 Yrs. and older United States\n25- NCT043\n92,778 Clinical Use of Stem\nCells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020\nDOC: September 2020 Both 40 to 60 Yrs. Turkey\n26- NCT043\n97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020\nDOC: June 2021 Both 18 to 80 Yrs. –\n27- NCT043\n90,139 Efficacy and Safety\nEvaluation of Mesenchymal Stem\nCells for the Treatment of Patients\nwith Respiratory\nDistress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020\nDOC: December 2020 Both 18 to 75 Yrs. Spain\n28- NCT042\n69,525 Umbilical Cord (UC)- Derived Mesenchymal\nStem Cells (MSCs)\nTreatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020\nDOC: September 2020 Both 18 to 75 Yrs. China"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T10","span":{"begin":396,"end":405},"obj":"Phenotype"},{"id":"T11","span":{"begin":904,"end":913},"obj":"Phenotype"},{"id":"T12","span":{"begin":1099,"end":1108},"obj":"Phenotype"},{"id":"T13","span":{"begin":1350,"end":1359},"obj":"Phenotype"},{"id":"T14","span":{"begin":1569,"end":1578},"obj":"Phenotype"},{"id":"T15","span":{"begin":2006,"end":2015},"obj":"Phenotype"},{"id":"T16","span":{"begin":2859,"end":2879},"obj":"Phenotype"},{"id":"T17","span":{"begin":3187,"end":3207},"obj":"Phenotype"},{"id":"T18","span":{"begin":3374,"end":3383},"obj":"Phenotype"},{"id":"T19","span":{"begin":3734,"end":3743},"obj":"Phenotype"},{"id":"T20","span":{"begin":5337,"end":5346},"obj":"Phenotype"},{"id":"T21","span":{"begin":6384,"end":6393},"obj":"Phenotype"}],"attributes":[{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020\nS.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country\n1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020\nDOC: June 2020 Both 18 Yrs. and older Brazil\n2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020\nDOC:September 2020 Both 18 Yrs. and older Jordan\n3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020\nDOC: July 2020 Both 18 to75 Yrs. China\n4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020\nDOC: July 2021 Both 18 to75 Yrs. –\n5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020\nDOC: December 2021 Both 18 to70 Yrs. China\n6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020\nDOC: February 2022 Both 18 to 65 Yrs. China\n7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs\n(MSCs-Exo) DOS: February 2020\nDOC: July 2020 Both 18 to75 Yrs. –\n8- NCT043\n36,254 Safety and Efficacy\nStudy of Allogeneic\nHuman Dental Pulp\nMesenchymal Stem\nCells to Treat Severe\nCOVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020\nDOC: March\n2021 Both 18 to 65 Yrs. China\n9- NCT043\n39,660 Clinical Research of Human Mesenchymal\nStem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020\nDOC: June 2020 Both 18 to 75 Yrs. China\n10- NCT043\n46,368 Bone Marrow-Derived\nMesenchymal Stem\nCell Treatment for\nSevere Patients With\nCoronavirus Disease\n2019 (COVID19) I and II Not\nRecruiting 20 BM-MSCs DOS: April 2020\nDOC: December\n2020 Both 18 to 75 Yrs. China\n11- NCT043\n52,803 Adipose Mesenchymal\nCells for Abatement of\nSARS CoV-2\nRespiratory\nCompromise in\nCOVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020\nDOC: April 2026 Both 18 to 90 Yrs. –\n12- NCT043\n49,631 A Clinical Trial to\nDetermine the Safety\nand Efficacy of Hope\nBiosciences\nAutologous\nMesenchymal Stem\nCell Therapy (HBadMSCs)\nto Provide\nProtection Against\nCOVID19 II Enrolling by\ninvitation 56 AD-MSCs DOS: May 2020\nDOC: December 2020 Both Child, Adult,\nOlder\nAdult United States\n13- NCT030\n42,143 Repair of Acute\nRespiratory Distress\nSyndrome by Stromal\nCell Administration\n(REALIST) (COVID19)\n(REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019\nDOC: October 2022 Both 16 Yrs. and older United Kingdom\n14- NCT043\n90,152 Safety and Efficacy of Intravenous Wharton’s\nJelly Derived\nMesenchymal Stem\nCells in Acute\nRespiratory Distress\nSyndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020\nDOC: May 2021 Both 18 to 80 Yrs. Colombia\n15- NCT043\n82,547 Treatment of\nCOVID19 Associated\nPneumonia with\nAllogenic Pooled\nOlfactory Mucosaderived\nMesenchymal\nStem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020\nDOC: June 2021 Both 18 to70 Yrs. Belarus\n16- NCT043\n66,323 Clinical Trial to Assess\nthe Safety and\nEfficacy of Intravenous\nAdministration of Allogeneic Adult\nMesenchymal Stem\nCells of Expanded\nAdipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020\nDOC: October 2021 Both 18 to 80 Yrs. –\n17- NCT043\n66,063 Mesenchymal Stem\nCell Therapy for SARS-CoV-2-related\nAcute Respiratory\nDistress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020\nDOC: December 2020 Both 18 to 65 Yrs. Iran\n18- NCT043\n77,334 Mesenchymal Stem\nCells (MSCs) in Inflammation-\nResolution Programs\nof Coronavirus\nDisease 2019\n(COVID19) Induced\nAcute Respiratory\nDistress Syndrome\n(ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020\nDOC: February 2021 Both 18 Yrs. and older Germany\n19- NCT043\n71,393 MSCs in COVID19\nARDS III Recruiting 300 MSCs\nRemestemcel-L DOS: April 30, 2020\nDOC: April 2022 Both 18 Yrs. and older United States\n20- NCT043\n62,189 Efficacy and Safety\nStudy of Allogeneic\nHB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020\nDOC: October 2020 Both Child,\nAdult,\nOlder\nAdult United States\n21- NCT043\n66,271 Clinical Trial of\nAllogeneic\nMesenchymal Cells\nfrom Umbilical Cord\nTissue in Patients with\nCOVID19 II Recruiting 106 UC-MSCs DOS: May 2020\nDOC: May 2021 Both 40 to 80 Yrs. Spain\n22- NCT043\n48,435 A Randomized,\nDouble-Blind,\nPlacebo-Controlled\nClinical Trial to Determine the Safety and Efficacy of Hope\nBiosciences\nAllogeneic\nMesenchymal Stem\nCell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020\nDOC: April 2021 Both Child,\nAdult, Older\nAdult United States\n23- NCT043\n71,601 Safety and Effectiveness of Mesenchymal Stem\nCells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020\nDOC: December 2022 Both 18 to 70 Yrs. China\n24- NCT043\n55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020\nDOC: May 2021 Both 18 Yrs. and older United States\n25- NCT043\n92,778 Clinical Use of Stem\nCells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020\nDOC: September 2020 Both 40 to 60 Yrs. Turkey\n26- NCT043\n97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020\nDOC: June 2021 Both 18 to 80 Yrs. –\n27- NCT043\n90,139 Efficacy and Safety\nEvaluation of Mesenchymal Stem\nCells for the Treatment of Patients\nwith Respiratory\nDistress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020\nDOC: December 2020 Both 18 to 75 Yrs. Spain\n28- NCT042\n69,525 Umbilical Cord (UC)- Derived Mesenchymal\nStem Cells (MSCs)\nTreatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020\nDOC: September 2020 Both 18 to 75 Yrs. China"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T198","span":{"begin":60,"end":67},"obj":"SP_7"},{"id":"T199","span":{"begin":709,"end":721},"obj":"GO:0070062"},{"id":"T201","span":{"begin":770,"end":771},"obj":"DG_47"},{"id":"T202","span":{"begin":967,"end":974},"obj":"SP_6;NCBITaxon:9606"},{"id":"T203","span":{"begin":977,"end":1022},"obj":"UBERON:0001754"},{"id":"T204","span":{"begin":1063,"end":1074},"obj":"UBERON:0003104"},{"id":"T206","span":{"begin":1261,"end":1266},"obj":"SP_6;NCBITaxon:9606"},{"id":"T207","span":{"begin":1282,"end":1293},"obj":"UBERON:0003104"},{"id":"T208","span":{"begin":1294,"end":1304},"obj":"CL:0000034"},{"id":"T209","span":{"begin":1325,"end":1328},"obj":"SP_7"},{"id":"T210","span":{"begin":1336,"end":1337},"obj":"UBERON:0002371"},{"id":"T217","span":{"begin":1452,"end":1460},"obj":"SP_7"},{"id":"T218","span":{"begin":1503,"end":1514},"obj":"UBERON:0003104"},{"id":"T219","span":{"begin":1540,"end":1541},"obj":"SP_7"},{"id":"T221","span":{"begin":1555,"end":1556},"obj":"UBERON:0007023"},{"id":"T222","span":{"begin":1559,"end":1566},"obj":"GO:0006281"},{"id":"T225","span":{"begin":1624,"end":1627},"obj":"UBERON:0003104"},{"id":"T228","span":{"begin":1682,"end":1686},"obj":"GO:0007608"},{"id":"T229","span":{"begin":1689,"end":1691},"obj":"UBERON:0003104"},{"id":"T232","span":{"begin":1753,"end":1755},"obj":"UBERON:0003104"},{"id":"T233","span":{"begin":1757,"end":1759},"obj":"UBERON:0001013"},{"id":"T235","span":{"begin":1769,"end":1780},"obj":"UBERON:0003104"},{"id":"T236","span":{"begin":1790,"end":1791},"obj":"SP_7"},{"id":"T239","span":{"begin":1808,"end":1812},"obj":"NCBITaxon:11118"},{"id":"T242","span":{"begin":1845,"end":1847},"obj":"SP_7"},{"id":"T243","span":{"begin":1851,"end":1853},"obj":"DG_47"},{"id":"T244","span":{"begin":1891,"end":1893},"obj":"SP_7"},{"id":"T247","span":{"begin":1902,"end":1904},"obj":"UBERON:0003104;CL:0000134"},{"id":"T252","span":{"begin":1951,"end":1953},"obj":"UBERON:0003104"},{"id":"T256","span":{"begin":1955,"end":1966},"obj":"UBERON:0003104"},{"id":"T257","span":{"begin":5350,"end":5361},"obj":"NCBITaxon:11118"},{"id":"T258","span":{"begin":5700,"end":5707},"obj":"SP_7"},{"id":"T259","span":{"begin":6080,"end":6091},"obj":"UBERON:0003104"},{"id":"T260","span":{"begin":6162,"end":6169},"obj":"SP_7"},{"id":"T261","span":{"begin":6277,"end":6291},"obj":"UBERON:0002331"},{"id":"T262","span":{"begin":6306,"end":6317},"obj":"UBERON:0003104"},{"id":"T263","span":{"begin":6318,"end":6328},"obj":"CL:0000034"},{"id":"T264","span":{"begin":6330,"end":6334},"obj":"DG_47"},{"id":"T265","span":{"begin":6365,"end":6376},"obj":"NCBITaxon:11118"},{"id":"T266","span":{"begin":6378,"end":6382},"obj":"NCBITaxon:10359"},{"id":"T128","span":{"begin":60,"end":67},"obj":"SP_7"},{"id":"T129","span":{"begin":336,"end":347},"obj":"CL:0000134;UBERON:0003104"},{"id":"T130","span":{"begin":348,"end":357},"obj":"CL:0000034"},{"id":"T131","span":{"begin":388,"end":395},"obj":"SP_7"},{"id":"T132","span":{"begin":527,"end":534},"obj":"SP_7"},{"id":"T133","span":{"begin":567,"end":578},"obj":"CL:0000134;UBERON:0003104"},{"id":"T134","span":{"begin":584,"end":607},"obj":"CL:0000134"},{"id":"T135","span":{"begin":708,"end":719},"obj":"CL:0000134;UBERON:0003104"},{"id":"T136","span":{"begin":720,"end":730},"obj":"CL:0000034"},{"id":"T137","span":{"begin":770,"end":777},"obj":"SP_7"},{"id":"T138","span":{"begin":877,"end":888},"obj":"NCBITaxon:11118"},{"id":"T139","span":{"begin":925,"end":931},"obj":"CL:0002540;UBERON:0001754"},{"id":"T140","span":{"begin":932,"end":936},"obj":"UBERON:0001754;CL:0002248"},{"id":"T141","span":{"begin":937,"end":948},"obj":"CL:0002540;UBERON:0003104"},{"id":"T142","span":{"begin":1075,"end":1084},"obj":"CL:0000034"},{"id":"T143","span":{"begin":1143,"end":1179},"obj":"NCBITaxon:11118"},{"id":"T144","span":{"begin":1261,"end":1266},"obj":"SP_6;NCBITaxon:9606"},{"id":"T145","span":{"begin":1267,"end":1276},"obj":"UBERON:0003422"},{"id":"T146","span":{"begin":1277,"end":1281},"obj":"UBERON:0003422;CL:0002364"},{"id":"T147","span":{"begin":1282,"end":1293},"obj":"CL:0000134;UBERON:0003422"},{"id":"T148","span":{"begin":1294,"end":1304},"obj":"CL:0000034"},{"id":"T149","span":{"begin":1331,"end":1342},"obj":"NCBITaxon:11118"},{"id":"T150","span":{"begin":1503,"end":1514},"obj":"UBERON:0003104"},{"id":"T151","span":{"begin":1526,"end":1534},"obj":"GO:0070062"},{"id":"T152","span":{"begin":1557,"end":1568},"obj":"NCBITaxon:11118"},{"id":"T153","span":{"begin":1624,"end":1628},"obj":"DG_47"},{"id":"T154","span":{"begin":1630,"end":1634},"obj":"DG_47"},{"id":"T155","span":{"begin":1757,"end":1763},"obj":"UBERON:0001091"},{"id":"T156","span":{"begin":1949,"end":1954},"obj":"SP_6;NCBITaxon:9606"},{"id":"T157","span":{"begin":1955,"end":1971},"obj":"CL:0000134;UBERON:0003104"},{"id":"T158","span":{"begin":1998,"end":2005},"obj":"SP_7"},{"id":"T159","span":{"begin":2129,"end":2135},"obj":"UBERON:0002371"},{"id":"T160","span":{"begin":2227,"end":2234},"obj":"SP_7"},{"id":"T161","span":{"begin":2357,"end":2374},"obj":"UBERON:0003104"},{"id":"T162","span":{"begin":2792,"end":2797},"obj":"UBERON:0007023"},{"id":"T163","span":{"begin":2931,"end":2938},"obj":"SP_7"},{"id":"T164","span":{"begin":2984,"end":2989},"obj":"PR:000014552"},{"id":"T165","span":{"begin":3224,"end":3233},"obj":"SP_7"},{"id":"T166","span":{"begin":3654,"end":3671},"obj":"UBERON:0007023"},{"id":"T167","span":{"begin":3703,"end":3709},"obj":"UBERON:0000479"},{"id":"T168","span":{"begin":3751,"end":3760},"obj":"SP_7"},{"id":"T169","span":{"begin":3901,"end":3911},"obj":"SP_7"},{"id":"T170","span":{"begin":3963,"end":3985},"obj":"DG_47"},{"id":"T171","span":{"begin":3991,"end":3999},"obj":"GO:0070062"},{"id":"T172","span":{"begin":4013,"end":4017},"obj":"DG_47"},{"id":"T173","span":{"begin":4019,"end":4023},"obj":"DG_47"},{"id":"T174","span":{"begin":4130,"end":4134},"obj":"DG_47"},{"id":"T175","span":{"begin":4176,"end":4195},"obj":"NCBITaxon:11118"},{"id":"T176","span":{"begin":4202,"end":4209},"obj":"SP_7"},{"id":"T177","span":{"begin":4369,"end":4377},"obj":"DG_47"},{"id":"T178","span":{"begin":4381,"end":4429},"obj":"SP_7"},{"id":"T179","span":{"begin":4594,"end":4608},"obj":"SP_7"},{"id":"T180","span":{"begin":4676,"end":4681},"obj":"UBERON:0007023"},{"id":"T181","span":{"begin":4779,"end":4788},"obj":"UBERON:0005297"},{"id":"T182","span":{"begin":4789,"end":4800},"obj":"UBERON:0001439"},{"id":"T183","span":{"begin":5124,"end":5144},"obj":"SP_7"},{"id":"T184","span":{"begin":5215,"end":5220},"obj":"UBERON:0007023"},{"id":"T185","span":{"begin":5294,"end":5305},"obj":"UBERON:0003104"},{"id":"T186","span":{"begin":5350,"end":5361},"obj":"NCBITaxon:11118"},{"id":"T187","span":{"begin":5507,"end":5514},"obj":"DG_48"},{"id":"T188","span":{"begin":5519,"end":5526},"obj":"SP_7"},{"id":"T189","span":{"begin":5700,"end":5709},"obj":"SP_7"},{"id":"T190","span":{"begin":5886,"end":5892},"obj":"UBERON:0007023"},{"id":"T191","span":{"begin":5898,"end":5905},"obj":"SP_7"},{"id":"T192","span":{"begin":6080,"end":6091},"obj":"UBERON:0003104"},{"id":"T193","span":{"begin":6162,"end":6171},"obj":"SP_7"},{"id":"T194","span":{"begin":6287,"end":6291},"obj":"UBERON:0001851"},{"id":"T195","span":{"begin":6306,"end":6322},"obj":"UBERON:0003104"},{"id":"T196","span":{"begin":6330,"end":6334},"obj":"DG_47"},{"id":"T197","span":{"begin":6365,"end":6376},"obj":"NCBITaxon:11118"}],"text":"Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020\nS.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country\n1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020\nDOC: June 2020 Both 18 Yrs. and older Brazil\n2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020\nDOC:September 2020 Both 18 Yrs. and older Jordan\n3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020\nDOC: July 2020 Both 18 to75 Yrs. China\n4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020\nDOC: July 2021 Both 18 to75 Yrs. –\n5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020\nDOC: December 2021 Both 18 to70 Yrs. China\n6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020\nDOC: February 2022 Both 18 to 65 Yrs. China\n7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs\n(MSCs-Exo) DOS: February 2020\nDOC: July 2020 Both 18 to75 Yrs. –\n8- NCT043\n36,254 Safety and Efficacy\nStudy of Allogeneic\nHuman Dental Pulp\nMesenchymal Stem\nCells to Treat Severe\nCOVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020\nDOC: March\n2021 Both 18 to 65 Yrs. China\n9- NCT043\n39,660 Clinical Research of Human Mesenchymal\nStem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020\nDOC: June 2020 Both 18 to 75 Yrs. China\n10- NCT043\n46,368 Bone Marrow-Derived\nMesenchymal Stem\nCell Treatment for\nSevere Patients With\nCoronavirus Disease\n2019 (COVID19) I and II Not\nRecruiting 20 BM-MSCs DOS: April 2020\nDOC: December\n2020 Both 18 to 75 Yrs. China\n11- NCT043\n52,803 Adipose Mesenchymal\nCells for Abatement of\nSARS CoV-2\nRespiratory\nCompromise in\nCOVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020\nDOC: April 2026 Both 18 to 90 Yrs. –\n12- NCT043\n49,631 A Clinical Trial to\nDetermine the Safety\nand Efficacy of Hope\nBiosciences\nAutologous\nMesenchymal Stem\nCell Therapy (HBadMSCs)\nto Provide\nProtection Against\nCOVID19 II Enrolling by\ninvitation 56 AD-MSCs DOS: May 2020\nDOC: December 2020 Both Child, Adult,\nOlder\nAdult United States\n13- NCT030\n42,143 Repair of Acute\nRespiratory Distress\nSyndrome by Stromal\nCell Administration\n(REALIST) (COVID19)\n(REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019\nDOC: October 2022 Both 16 Yrs. and older United Kingdom\n14- NCT043\n90,152 Safety and Efficacy of Intravenous Wharton’s\nJelly Derived\nMesenchymal Stem\nCells in Acute\nRespiratory Distress\nSyndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020\nDOC: May 2021 Both 18 to 80 Yrs. Colombia\n15- NCT043\n82,547 Treatment of\nCOVID19 Associated\nPneumonia with\nAllogenic Pooled\nOlfactory Mucosaderived\nMesenchymal\nStem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020\nDOC: June 2021 Both 18 to70 Yrs. Belarus\n16- NCT043\n66,323 Clinical Trial to Assess\nthe Safety and\nEfficacy of Intravenous\nAdministration of Allogeneic Adult\nMesenchymal Stem\nCells of Expanded\nAdipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020\nDOC: October 2021 Both 18 to 80 Yrs. –\n17- NCT043\n66,063 Mesenchymal Stem\nCell Therapy for SARS-CoV-2-related\nAcute Respiratory\nDistress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020\nDOC: December 2020 Both 18 to 65 Yrs. Iran\n18- NCT043\n77,334 Mesenchymal Stem\nCells (MSCs) in Inflammation-\nResolution Programs\nof Coronavirus\nDisease 2019\n(COVID19) Induced\nAcute Respiratory\nDistress Syndrome\n(ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020\nDOC: February 2021 Both 18 Yrs. and older Germany\n19- NCT043\n71,393 MSCs in COVID19\nARDS III Recruiting 300 MSCs\nRemestemcel-L DOS: April 30, 2020\nDOC: April 2022 Both 18 Yrs. and older United States\n20- NCT043\n62,189 Efficacy and Safety\nStudy of Allogeneic\nHB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020\nDOC: October 2020 Both Child,\nAdult,\nOlder\nAdult United States\n21- NCT043\n66,271 Clinical Trial of\nAllogeneic\nMesenchymal Cells\nfrom Umbilical Cord\nTissue in Patients with\nCOVID19 II Recruiting 106 UC-MSCs DOS: May 2020\nDOC: May 2021 Both 40 to 80 Yrs. Spain\n22- NCT043\n48,435 A Randomized,\nDouble-Blind,\nPlacebo-Controlled\nClinical Trial to Determine the Safety and Efficacy of Hope\nBiosciences\nAllogeneic\nMesenchymal Stem\nCell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020\nDOC: April 2021 Both Child,\nAdult, Older\nAdult United States\n23- NCT043\n71,601 Safety and Effectiveness of Mesenchymal Stem\nCells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020\nDOC: December 2022 Both 18 to 70 Yrs. China\n24- NCT043\n55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020\nDOC: May 2021 Both 18 Yrs. and older United States\n25- NCT043\n92,778 Clinical Use of Stem\nCells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020\nDOC: September 2020 Both 40 to 60 Yrs. Turkey\n26- NCT043\n97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020\nDOC: June 2021 Both 18 to 80 Yrs. –\n27- NCT043\n90,139 Efficacy and Safety\nEvaluation of Mesenchymal Stem\nCells for the Treatment of Patients\nwith Respiratory\nDistress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020\nDOC: December 2020 Both 18 to 75 Yrs. Spain\n28- NCT042\n69,525 Umbilical Cord (UC)- Derived Mesenchymal\nStem Cells (MSCs)\nTreatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020\nDOC: September 2020 Both 18 to 75 Yrs. China"}